<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pcbi</journal-id><journal-id journal-id-type="flc">plcb</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1371/journal.pcbi.0020001</article-id><article-id pub-id-type="publisher-id">05-PLCB-RA-0201R3</article-id><article-id pub-id-type="sici">plcb-02-01-05</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Computational Biology</subject><subject>Molecular Biology</subject></subj-group><subj-group subj-group-type="System Taxonomy"><subject>Homo (human)</subject></subj-group></article-categories><title-group><article-title>Computational Analysis and Prediction of the Binding Motif and Protein Interacting Partners of the Abl SH3 Domain</article-title><alt-title alt-title-type="running-head">Prediction of Abl SH3 Binding Partners</alt-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hou</surname><given-names>Tingjun</given-names></name><xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref><xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref><xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>McLaughlin</surname><given-names>William A</given-names></name><xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref><xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lu</surname><given-names>Benzhuo</given-names></name><xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref><xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref><xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref><xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref></contrib></contrib-group><aff id="aff1">
				<label>1</label><addr-line> Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States of America
			</addr-line></aff><aff id="aff2">
				<label>2</label><addr-line> Center for Theoretical Biological Physics, University of California San Diego, La Jolla, California, United States of America
			</addr-line></aff><contrib-group><contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Murray</surname><given-names>Diana</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Cornell University, United States of America</aff><author-notes><fn fn-type="con" id="ack2"><p>TH, KC, and WW conceived and designed the experiments. TH performed the experiments. TH, KC, WAM, and BL analyzed the data. TH and WW wrote the paper.</p></fn><corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">wei-wang@ucsd.edu</email></corresp><fn fn-type="conflict" id="ack1"><p> The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="ppub"><month>1</month><year>2006</year></pub-date><pub-date pub-type="epub"><day>27</day><month>1</month><year>2006</year></pub-date><volume>2</volume><issue>1</issue><elocation-id>e1</elocation-id><history><date date-type="received"><day>12</day><month>8</month><year>2005</year></date><date date-type="accepted"><day>5</day><month>12</month><year>2005</year></date></history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2006</copyright-year><copyright-holder>Hou et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Protein-protein interactions, particularly weak and transient ones, are often mediated by peptide recognition domains, such as Src Homology 2 and 3 (SH2 and SH3) domains, which bind to specific sequence and structural motifs. It is important but challenging to determine the binding specificity of these domains accurately and to predict their physiological interacting partners. In this study, the interactions between 35 peptide ligands (15 binders and 20 non-binders) and the Abl SH3 domain were analyzed using molecular dynamics simulation and the Molecular Mechanics/Poisson-Boltzmann Solvent Area method. The calculated binding free energies correlated well with the rank order of the binding peptides and clearly distinguished binders from non-binders. Free energy component analysis revealed that the van der Waals interactions dictate the binding strength of peptides, whereas the binding specificity is determined by the electrostatic interaction and the polar contribution of desolvation. The binding motif of the Abl SH3 domain was then determined by a virtual mutagenesis method, which mutates the residue at each position of the template peptide relative to all other 19 amino acids and calculates the binding free energy difference between the template and the mutated peptides using the Molecular Mechanics/Poisson-Boltzmann Solvent Area method. A single position mutation free energy profile was thus established and used as a scoring matrix to search peptides recognized by the Abl SH3 domain in the human genome. Our approach successfully picked ten out of 13 experimentally determined binding partners of the Abl SH3 domain among the top 600 candidates from the 218,540 decapeptides with the PXXP motif in the SWISS-PROT database. We expect that this physical-principle based method can be applied to other protein domains as well.</p></abstract><abstract abstract-type="synopsis"><title>Synopsis</title><p>One of the central questions of molecular biology is to understand how signals are transduced in the cell. Intracellular signal transduction is mainly achieved through cascades of protein-protein interactions, which are often mediated by peptide-binding modular domains, such as Src Homology 2 and 3 (SH2 and SH3). Each family of these domains binds to peptides with specific sequence and structural characteristics. To reconstruct the protein-protein interaction networks mediated by modular domains, one must identify the peptide motifs recognized by these domains and understand the mechanism of binding specificity. These questions are challenging because the domain-peptide interactions are usually weak and transient. Here, the authors took a physical-principles approach to address these difficult questions for the SH3 domain of human protein Abl, which binds to peptides containing the PXXP motif (where P is proline and X is any amino acid). They generated a position-specific scoring matrix to represent the binding motif of the Abl SH3 domain. Analysis on the binding free energy components suggested insights into how the binding specificity is achieved. Most known protein interacting partners of the Abl SH3 domain were correctly identified using the position-specific scoring matrix, and other potential interacting partners were also suggested.</p></abstract><counts><page-count count="10"/></counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group><custom-meta><meta-name>Citation:</meta-name><meta-value>Hou T, Chen K, McLaughlin WA, Lu B, Wang W (2006) Computational analysis and prediction of the binding motif and protein interacting partners of the Abl SH3 domain. PLoS Comput Biol 2(1): e1.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The interactions between protein domains and their peptide ligands play critical roles in signal transduction and many other key biological processes. Because domain-peptide interactions are usually weak and transient, and often depend upon post-translational modification, they tend to be under-represented in high-throughput and computational studies [<xref ref-type="bibr" rid="pcbi-0020001-b001">1</xref>], thus highlighting the need to develop new methods to identify these interactions. The Src Homology 3 (SH3) domain is the most abundant modular domain in the human proteome and presents in a wide variety of proteins, such as kinases, lipases, GTPases, and adaptor proteins, to orchestrate diverse cellular processes [<xref ref-type="bibr" rid="pcbi-0020001-b002">2</xref>–<xref ref-type="bibr" rid="pcbi-0020001-b006">6</xref>]. SH3 domains are 50–70 amino acids long and consist of five β-strands arranged into two sheets packed at right angles. They recognize the proline-rich peptides with the consensus motif PXXP (where P is proline and X is any amino acid) [<xref ref-type="bibr" rid="pcbi-0020001-b007">7</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b008">8</xref>] that forms a left-handed poly-proline type II (PPII) helix [<xref ref-type="bibr" rid="pcbi-0020001-b009">9</xref>]. Depending on the position of the positive residue in the peptide sequence, the majority of SH3 ligands fall into two classes that bind to the protein in opposite orientations [<xref ref-type="bibr" rid="pcbi-0020001-b010">10</xref>]: N-terminal to C-terminal (class I) or C-terminal to N-terminal (class II). Class I peptides typically consist of a core motif of RXLPX#P (where # is usually a hydrophobic residue), whereas the class II peptides contain a core motif of PX#PXR. In class I peptides, the proline residues in bold occupy the sites in the hydrophobic pocket that are normally referred as position P<sub>0</sub> and P<sub>3</sub>, while the Arg residue occupies position P<sub>−3</sub> (the positions are often dubbed as P<sub>−3</sub>, P<sub>−2</sub>, P<sub>−1</sub>, P<sub>0</sub>, P<sub>1</sub>, P<sub>2,</sub> and P<sub>3</sub> from N-terminal to C-terminal, namely from R to P, in the motif RXLPX#P [<xref ref-type="bibr" rid="pcbi-0020001-b002">2</xref>]). A notable variance of this motif is the one recognized by the Abl SH3 domain, which contains a tyrosine or a large hydrophobic residue at position P<sub>−3</sub>.</p><p>The binding specificity of a specific SH3 domain is determined by the flanking residues around the core motif PXXP [<xref ref-type="bibr" rid="pcbi-0020001-b010">10</xref>]. Understanding the molecular basis of the specificity for each SH3 domain and identifying the sequence motif it recognizes are crucial to reconstruct the complete protein-protein interaction networks mediated by SH3 domains. Both experimental and computational methods have been developed to tackle this problem. Peptide library screening is often used to determine the binding motif of a SH3 domain, in which the binding peptides are sequenced and aligned to generate a frequency matrix representing the amino acid preference at each position [<xref ref-type="bibr" rid="pcbi-0020001-b011">11</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b012">12</xref>]. Bias may be introduced by not completely sampling all possible peptides, not quantitatively weighting the contribution of peptides to the matrix based on their binding strength and/or not distinguishing peptides bound to the SH3 domain in different binding modes. Computational methods such as Scansite [<xref ref-type="bibr" rid="pcbi-0020001-b013">13</xref>], SPOT [<xref ref-type="bibr" rid="pcbi-0020001-b014">14</xref>], and VIP [<xref ref-type="bibr" rid="pcbi-0020001-b015">15</xref>] methods have been developed to predict interacting proteins of a domain. The performance of Scansite totally depends on the accuracy of the frequency matrix determined by the peptide library experiments. SPOT is limited by the relatively small number of residue contact pairs between SH3 domains and peptides. The performance of the VIP method can be improved if more conformational sampling is done and more rigorous binding energy prediction method, including the conformational energy change and the desolvation contribution upon peptide binding, is applied.</p><p>In this study, we analyzed the binding specificity of the SH3 domain of the human protein Abl. The Molecular Mechanics/Poisson-Boltzmann Solvent Area (MM/PBSA) method [<xref ref-type="bibr" rid="pcbi-0020001-b016">16</xref>] was first applied to calculate the binding free energies between the Abl SH3 domains and 35 ten-residue-long peptides (15 binders and 20 non-binders). As a validation of the MM/PBSA method on the domain-peptide system, the calculated binding free energies of the 15 known binders correlated well with the experimental values [<xref ref-type="bibr" rid="pcbi-0020001-b017">17</xref>] and were distinct from those of the non-binders. Analysis of the molecular dynamics (MD) trajectories and binding free energy components shed light into understanding the mechanism of the binding specificity of the Abl SH3 domain. The residue preference at each position of the peptide ligand was then studied systematically by single position mutation and MM/PBSA calculations, which we call the virtual mutagenesis (VM) method [<xref ref-type="bibr" rid="pcbi-0020001-b018">18</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b019">19</xref>]. A single position mutation free energy profile (SPMFEP) was established from such analysis to quantitatively represent the binding motif and was in good agreement with the experimental measurements. We used SPMFEP as a scoring matrix to search the SWISS-PROT database for potential binding partners of the Abl SH3 domain. Most experimentally determined binding proteins of the Abl SH3 domain were ranked in the top 600 candidates among about 6.2 × 10<sup>7</sup> decapeptides in the database and many promising candidates were also suggested.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Molecular Basis of the Binding Specificity of the Abl SH3 Domain</title><sec id="s2a1"><title>The calculated binding free energies correlate well with the experimental values.</title><p>We first evaluated the performance of the MM/PBSA method on calculating the binding free energies of the Abl SH3 domain and its peptide ligands (15 binders and 20 non-binders). As shown in <xref ref-type="table" rid="pcbi-0020001-t001">Table 1</xref> and <xref ref-type="fig" rid="pcbi-0020001-g001">Figure 1</xref>, the calculated relative binding free energies of the 15 known binders show good correlation with the experimental values (the correlation coefficient <italic>r</italic> and standard deviation [SD] are 0.82 and 1.7, respectively). We then analyzed the free energy components to search for the dominant factor that dictates the binding specificity (<xref ref-type="table" rid="pcbi-0020001-t001">Table 1</xref>). As the favorable electrostatic interaction between the peptide and the SH3 domain Δ<italic>E</italic><sub>ele</sub> is canceled by the unfavorable electrostatic contribution to desolvation Δ<italic>G</italic><sub>PB</sub>, the van der Waals interaction Δ<italic>E</italic><sub>vdw</sub> is the most favorable component of the binding free energy. The favorable Δ<italic>E</italic><sub>vdw</sub> is mainly from the interactions between the conserved proline residues of the PXXP motif and the hydrophobic surface that is formed by Tyr7, Phe9, Trp36, Tyr52, and Pro49 of the Abl SH3 domain and conserved in almost all SH3 domains. To investigate which energetic factor determines the relative binding affinities of these 15 binders, we compared the correlations between the measured binding free energies and each of the four free energy components, Δ<italic>E</italic><sub>ele</sub>, Δ<italic>E</italic><sub>vdw</sub>, Δ<italic>G</italic><sub>PB</sub>, and Δ<italic>G</italic><sub>SA</sub>. None of these components shows good correlation with the experimental values and the largest correlation coefficient is only 0.43 for Δ<italic>E</italic><sub>ele</sub>, which suggests that no individual free energy component dominates the binding specificity. We then analyzed the non-polar (Δ<italic>E</italic><sub>vdw</sub> + Δ<italic>G</italic><sub>SA</sub>) and the electrostatic contribution (Δ<italic>E</italic><sub>ele</sub> + Δ<italic>G</italic><sub>PB</sub>) to the binding free energy. The electrostatic contribution correlates well with the binding free energies (<italic>r</italic> = 0.73, SD = 1.6) while the non-polar contribution does not show any correlation (<italic>r</italic> = −0.32, SD = 2.0). It suggests that the binding preference of these peptides is mainly determined by the electrostatic contribution to binding.</p><table-wrap content-type="2col" id="pcbi-0020001-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.t001</object-id><label>Table 1</label><caption><p>Energetic Components and Binding Affinities for the 15 Peptide Ligands of the Abl SH3 Domain (kcal/mol)</p></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.t001" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb1col1" align="left" charoff="0" char=""/><col id="tb1col2" align="left" charoff="0" char=""/><col id="tb1col3" align="char" charoff="0" char="."/><col id="tb1col4" align="char" charoff="0" char="."/><col id="tb1col5" align="left" charoff="0" char=""/><col id="tb1col6" align="char" charoff="0" char="."/><col id="tb1col7" align="left" charoff="0" char=""/><col id="tb1col8" align="left" charoff="0" char=""/><col id="tb1col9" align="left" charoff="0" char=""/></colgroup><thead><tr><td align="left"><hr/>Name</td><td><hr/>Description</td><td><hr/>Value without Phosphate Control</td><td><hr/>Value with Phosphate Control</td><td><hr/>Units</td><td><hr/>Sensitivity</td><td><hr/>Reference</td><td><hr/>Class<sup>a</sup></td><td><hr/>Equation</td></tr></thead><tbody><tr><td><italic>r</italic></td><td>Dehydrogenase model parameter</td><td>4.2530</td><td>4.5807</td><td>Unitless</td><td>4.92</td><td>&mdash;</td><td>A</td><td>1</td></tr><tr><td><italic>k</italic><sub>Pi,1</sub></td><td>Dehydrogenase model parameter</td><td>0.13890</td><td>0.13413</td><td>mM</td><td>1.41</td><td>&mdash;</td><td>A</td><td>1</td></tr><tr><td><italic>k</italic><sub>Pi,2</sub></td><td>Dehydrogenase model parameter</td><td>0.62396</td><td>0.67668</td><td>mM</td><td>1.01</td><td>&mdash;</td><td>A</td><td>1</td></tr><tr><td><italic>X</italic><sub>DH</sub></td><td>Dehydrogenase activity</td><td>0.10990</td><td>0.09183</td><td>mol s<sup>&minus;1</sup> M<sup>&minus;1</sup> (l mito volume)<sup>&minus;1</sup></td><td>2.94</td><td>&mdash;</td><td>A</td><td>1</td></tr><tr><td><italic>X</italic><sub>C1</sub></td><td>Complex I activity</td><td>0.54088</td><td>0.36923</td><td>mol s<sup>&minus;1</sup> M<sup>&minus;1</sup> (l mito volume)<sup>&minus;1</sup></td><td>0.033</td><td>&mdash;</td><td>A</td><td>3</td></tr><tr><td><italic>X</italic><sub>C3</sub></td><td>Complex III activity</td><td>0.14483</td><td>0.091737</td><td>mol s<sup>&minus;1</sup> M<sup>&minus;1</sup> (l mito volume)<sup>&minus;1</sup></td><td>0.19</td><td>&mdash;</td><td>A</td><td>7</td></tr><tr><td><italic>X</italic><sub>C4</sub></td><td>Complex IV activity</td><td>2.2669 &times; 10<sup>&minus;5</sup></td><td>3.2562 &times; 10<sup>&minus;5</sup></td><td>mol s<sup>&minus;1</sup> M<sup>&minus;1</sup> (l mito volume)<sup>&minus;1</sup></td><td>0.33</td><td>&mdash;</td><td>A</td><td>9</td></tr><tr><td><italic>X</italic><sub>F1</sub></td><td>F<sub>1</sub>F<sub>0</sub> ATPase activity</td><td>154.82</td><td>150.93</td><td>mol s<sup>&minus;1</sup> M<sup>&minus;2</sup> (l mito volume)<sup>&minus;1</sup></td><td>0.0005</td><td>&mdash;</td><td>A</td><td>11</td></tr><tr><td><italic>X</italic><sub>ANT</sub></td><td>ANT activity</td><td>0.010723</td><td>0.0079204</td><td>mol s<sup>&minus;1</sup> (l mito volume)<sup>&minus;1</sup></td><td>1.84</td><td>&mdash;</td><td>A</td><td>14</td></tr><tr><td><italic>X</italic><sub>PiHt</sub></td><td>H<sup>&plus;</sup>/Pi<sup>&minus;</sup> co-transport activity</td><td>3.7442 &times; 10<sup>5</sup></td><td>3.3943 &times; 10<sup>5</sup></td><td>mol s<sup>&minus;1</sup> M<sup>&minus;1</sup> (l mito volume)<sup>&minus;1</sup></td><td>0.14</td><td>&mdash;</td><td>A</td><td>16</td></tr><tr><td><italic>k</italic><sub>PiHt</sub></td><td>H<sup>&plus;</sup>/Pi<sup>&minus;</sup> co-transport parameter</td><td>0.72911</td><td>0.45082</td><td>mM</td><td>0.025</td><td>&mdash;</td><td>A</td><td>16</td></tr><tr><td><italic>X</italic><sub>KH</sub></td><td>K<sup>&plus;</sup>/H<sup>&plus;</sup> antiporter activity</td><td>3.1775 &times; 10<sup>7</sup></td><td>2.9802 &times; 10<sup>7</sup></td><td>mol s<sup>&minus;1</sup> M<sup>&minus;2</sup> (l mito volume)<sup>&minus;1</sup></td><td>0.0022</td><td>&mdash;</td><td>A</td><td>21</td></tr><tr><td><italic>X</italic><sub>K</sub></td><td>Passive potassium transport activity</td><td>0</td><td>0</td><td>mol s<sup>&minus;1</sup> mV<sup>&minus;1</sup> M<sup>&minus;1</sup> (l mito volume)<sup>&minus;1</sup></td><td>0</td><td>&mdash;</td><td>A</td><td>20</td></tr><tr><td><italic>X</italic><sub>Hle</sub></td><td>Proton leak activity</td><td>250.02</td><td>250.00</td><td>mol s<sup>&minus;1</sup> mV<sup>&minus;1</sup> M<sup>&minus;1</sup> (l mito volume)<sup>&minus;1</sup></td><td>1.08</td><td>&mdash;</td><td>A</td><td>19</td></tr><tr><td><italic>k</italic><sub>Pi,3</sub></td><td>Complex III/Pi parameter</td><td>&mdash;</td><td>0.19172</td><td>mM</td><td>0.077</td><td>&mdash;</td><td>A</td><td>24</td></tr><tr><td><italic>k</italic><sub>Pi,4</sub></td><td>Complex III/Pi parameter</td><td>&mdash;</td><td>25.310</td><td>mM</td><td>0.002</td><td>&mdash;</td><td>A</td><td>24</td></tr><tr><td><italic>n<sub>A</sub></italic></td><td>H<sup>&plus;</sup> stoichiometric coefficient for F<sub>1</sub>F<sub>0</sub> ATPase</td><td>3</td><td>3</td><td>Unitless</td><td></td><td>&lsqb;48&rsqb;<sup>b</sup></td><td>B</td><td>11, 22</td></tr><tr><td><italic>K</italic><sub>Mg-ATP</sub></td><td>Mg-ATP binding constant</td><td>24.0 &times; 10<sup>&minus;6</sup></td><td>24.0 &times; 10<sup>&minus;6</sup></td><td>M</td><td></td><td>&lsqb;32&rsqb;</td><td>B</td><td>11, 12</td></tr><tr><td><italic>K</italic><sub>Mg-ADP</sub></td><td>Mg-ADP binding constant</td><td>347.0 &times; 10<sup>&minus;6</sup></td><td>347.0 &times; 10<sup>&minus;6</sup></td><td>M</td><td></td><td>&lsqb;32&rsqb;</td><td>B</td><td>11, 12</td></tr><tr><td><italic>k</italic><sub>dH</sub></td><td>H<sub>2</sub>PO<sub>4</sub><sup>&minus;</sup> proton dissociate constant</td><td>1.7783 &times; 10<sup>&minus;7</sup></td><td>1.7783 &times; 10<sup>&minus;7</sup></td><td>M</td><td></td><td>&lsqb;49&rsqb;</td><td>B</td><td>15</td></tr><tr><td><italic>p</italic><sub>Pi</sub></td><td>Mitochondrial membrane permeability to inorganic phosphate</td><td>327</td><td>327</td><td>&mu;m s<sup>&minus;1</sup></td><td></td><td>&lsqb;8&rsqb;</td><td>B</td><td>13</td></tr><tr><td><italic>p</italic><sub>A</sub></td><td>Mitochondrial outer membrane permeability to nucleotides</td><td>85.0</td><td>85.0</td><td>&mu;m s<sup>&minus;1</sup></td><td></td><td>&lsqb;33&rsqb;</td><td>B</td><td>13</td></tr><tr><td><italic>K</italic><sub>AK</sub></td><td>AK equilibrium constant</td><td>0.4331</td><td>0.4331</td><td>Unitless</td><td></td><td>&lsqb;49&rsqb;<sup>c</sup></td><td>B</td><td>18</td></tr><tr><td><italic>k</italic><sub>m,ADP</sub></td><td>ANT Michaelis&ndash;Menten constant</td><td>3.5 &times; 10<sup>&minus;6</sup></td><td>3.5 &times; 10<sup>&minus;6</sup></td><td>M</td><td></td><td>&lsqb;6,8&rsqb;<sup>d</sup></td><td>B</td><td>14</td></tr><tr><td><italic>k</italic><sub>O<sub>2</sub></sub></td><td>Saturation constant for oxygen consumption</td><td>1.20 &times; 10<sup>&minus;4</sup></td><td>1.20 &times; 10<sup>&minus;4</sup></td><td>M</td><td></td><td>&lsqb;6,8&rsqb;<sup>d</sup></td><td>B</td><td>9</td></tr><tr><td>NAD<sub>tot</sub></td><td>Total matrix NAD(H) concentration</td><td>2.97</td><td>2.97</td><td>mM</td><td></td><td>&lsqb;6,8&rsqb;<sup>d</sup></td><td>B</td><td>23</td></tr><tr><td>Q<sub>tot</sub></td><td>Total matrix ubiquinol concentration</td><td>1.35</td><td>1.35</td><td>mM</td><td></td><td>&lsqb;6,8&rsqb;<sup>d</sup></td><td>B</td><td>23</td></tr><tr><td>cytC<sub>tot</sub></td><td>Total IM cytochrome c concentration</td><td>2.70</td><td>2.70</td><td>mM</td><td></td><td>&lsqb;6,8&rsqb;<sup>e</sup></td><td>B</td><td>9, 23</td></tr><tr><td>A<sub>tot</sub></td><td>Total matrix ATP &plus; ADP concentration</td><td>10</td><td>10</td><td>mM</td><td></td><td>&lsqb;6,8&rsqb;<sup>d</sup></td><td>B</td><td>23</td></tr><tr><td>V<sub>x</sub></td><td>Matrix water volume per total mito volume</td><td>0.6435</td><td>0.6435</td><td>Unitless</td><td></td><td>&lsqb;50&rsqb;<sup>f</sup></td><td>B</td><td>22</td></tr><tr><td>V<sub>i</sub></td><td>IM water fraction per total cell volume</td><td>0.0715</td><td>0.0715</td><td>Unitless</td><td></td><td>&lsqb;50&rsqb;<sup>f</sup></td><td>B</td><td>22</td></tr><tr><td>&gamma;</td><td>Outer membrane area per mito volume</td><td>5.99</td><td>5.99</td><td>&mu;m<sup>&minus;1</sup></td><td></td><td>&lsqb;35&rsqb;</td><td>B</td><td>13</td></tr><tr><td>C<sub>IM</sub></td><td>Capacitance of inner membrane</td><td>6.75 &times; 10<sup>&minus;6</sup></td><td>6.75 &times; 10<sup>&minus;6</sup></td><td>mol (l mito volume)<sup>&minus;1</sup> mV<sup>&minus;1</sup></td><td></td><td>&lsqb;34&rsqb;</td><td>B</td><td>22</td></tr><tr><td><italic>X</italic><sub>AK</sub></td><td>AK activity</td><td>1.0 &times; 10<sup>6</sup></td><td>1.0 &times; 10<sup>6</sup></td><td>mol s<sup>&minus;1</sup> M<sup>&minus;2</sup> (l mito volume)<sup>&minus;1</sup></td><td></td><td>&mdash;</td><td>C</td><td>18</td></tr><tr><td><italic>X</italic><sub>MgA</sub></td><td>Mg<sup>2&plus;</sup> binding activity</td><td>1.0 &times; 10<sup>6</sup></td><td>1.0 &times; 10<sup>6</sup></td><td>mol s<sup>&minus;1</sup> M<sup>&minus;2</sup> (l mito volume)<sup>&minus;1</sup></td><td></td><td>&mdash;</td><td>C</td><td>12</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt101"><p><sup>a</sup>See text for explanation of parameter classes.</p></fn><fn id="nt102"><p><sup>b</sup>Value consistent with accepted range.</p></fn><fn id="nt103"><p><sup>c</sup>Computed from thermodynamic data tabulated in cited reference.</p></fn><fn id="nt104"><p><sup>d</sup>Value used is taken from previous modeling studies, not direct experimental measure.</p></fn><fn id="nt105"><p><sup>e</sup>Value used is ten times the value used in cited references. See text for explanation.</p></fn><fn id="nt106"><p><sup>f</sup>Matrix volume is taken as 90&percnt; of total mitochondrial volume; IM space volume as 10&percnt;.</p></fn></table-wrap-foot> --></table-wrap><fig id="pcbi-0020001-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.g001</object-id><label>Figure 1</label><caption><title>The Correlations between Experimental and Predicted Relative Binding Free Energies of the 15 Binders of the Abl SH3 Domain</title></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.g001" xlink:type="simple"/></fig><p>We also found that the conformational change of the peptide upon binding Δ<italic>E</italic><sub>conf_pep</sub> was important (<italic>r</italic> = 0.54, SD =1.8). The sum of Δ<italic>E</italic><sub>ele</sub>, Δ<italic>E</italic><sub>vdw</sub>, Δ<italic>G</italic><sub>PB</sub>, Δ<italic>G</italic><sub>SA</sub>, and Δ<italic>E</italic><sub>conf_pep</sub> correlates well with the binding free energies (<italic>r</italic> = 0.79, SD =1.8) whereas the sum of the first four terms does not (<italic>r</italic> = 0.52). Our calculations highlight the crucial effect of the change of the conformational energy of peptide to the affinities, which is not always appropriately considered [<xref ref-type="bibr" rid="pcbi-0020001-b020">20</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b021">21</xref>]. Inclusion of the conformational entropy −TΔS in the free energy calculation only slightly improves the correlation coefficient from 0.79–0.82, which suggests that the conformational entropy is not the determinant factor of the binding specificity of the binders.</p><p>The binding free energies and the free energy components for the 20 non-binders of the Abl SH3 domain were also calculated (<xref ref-type="supplementary-material" rid="pcbi-0020001-st001">Table S1</xref>). Two distributions of the binding free energies for binders and non-binders are distinct (<xref ref-type="fig" rid="pcbi-0020001-g002">Figure 2</xref>), which indicates that the MM/PBSA method can distinguish binders from non-binders. We also found that most non-binders preferred unbound conformations. First, the average conformational entropy change upon binding −TΔS for binders and non-binders are 32.1 kcal/mol and 35.9 kcal/mol, respectively, indicating that most non-binders lost more entropy upon binding than did binders. Second, the change of conformational energy for binders and non-binders are also significantly different: the average value for binders and non-binders are 2.0 kcal/mol and 4.3 kcal/mol, respectively.</p><fig id="pcbi-0020001-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.g002</object-id><label>Figure 2</label><caption><title>The Distributions of the Predicted Binding Free Energies for Binders and Non-Binders of the Abl SH3 Domain</title></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.g002" xlink:type="simple"/></fig></sec><sec id="s2a2"><title>The binding motif can be revealed by the VM method.</title><p>To understand the mechanism of the binding specificity, we need to determine the binding motif of the domain. We analyzed the amino acid preference at each position of the peptide using the VM method (see <xref ref-type="sec" rid="s4">Materials and Methods</xref>). We compared our results with the available experimental measurements at positions P<sub>3</sub>, P<sub>0</sub>, P<sub>−3,</sub> and P<sub>−5</sub> (<xref ref-type="supplementary-material" rid="pcbi-0020001-st003">Tables S3</xref>–<xref ref-type="supplementary-material" rid="pcbi-0020001-st006">S6</xref>) [<xref ref-type="bibr" rid="pcbi-0020001-b017">17</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b022">22</xref>]. These four positions are particularly important for the peptide binding: the two usually conserved Pro residues at P<sub>3</sub> and P<sub>0</sub> ensure strong binding affinity and residues at P<sub>−3</sub>, and P<sub>−5</sub> are essential to the binding specificity [<xref ref-type="bibr" rid="pcbi-0020001-b009">9</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b010">10</xref>]. To determine the residues of the Abl SH3 domain that are important for peptide binding, the contribution of each SH3 domain residue to binding with the template peptide APSYSP<bold>P</bold>PP<bold>P</bold> (the two conserved Pro residues are in bold) was analyzed (the polar contribution to desolvation was calculated using the GB/SA method implemented in the <italic>mm_pbsa</italic> module of AMBER 8 for the sake of efficiency.) (<xref ref-type="supplementary-material" rid="pcbi-0020001-st007">Table S7</xref>) [<xref ref-type="bibr" rid="pcbi-0020001-b019">19</xref>].</p><p>In the crystal structure of APSYSPPPPP complexed with the Abl SH3 domain, the residue at position P<sub>−5</sub> in the peptide occupies a hydrophobic pocket of the SH3 domain. Proline at this position has relatively strong van der Waals interactions with Trp36 (−1.3 kcal/mol) and Trp47 (−0.9 kcal/mol) in the Abl SH3 domain (<xref ref-type="supplementary-material" rid="pcbi-0020001-st007">Table S7</xref>). Several other residues, Asn, Leu, Met, Phe, Tyr, and Val, are also strongly favored at this position (<xref ref-type="fig" rid="pcbi-0020001-g003">Figure 3</xref>A). It is worth pointing out that the mutation of Pro to Tyr or Phe, does not significantly impair the van der Waals interaction between the peptide and the SH3 domain due to the conformational change of the peptide backbone. Our predicted preference based on free energy calculations is consistent with the experimental results: Pro is the most preferred, whereas other residues especially hydrophobic ones (Phe, Leu, Met, Val, and Trp) are also favored [<xref ref-type="bibr" rid="pcbi-0020001-b022">22</xref>].</p><fig id="pcbi-0020001-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.g003</object-id><label>Figure 3</label><caption><title>The Preference of Residue Based on the Binding Free Energy Difference between the Mutated Peptide and the Template Peptide</title><p>The preference of residue at positions (A) P<sub>−5</sub>, (B) P<sub>−3</sub>, (C) P<sub>0</sub>, and (D) P<sub>3</sub> based on the binding free energy difference between the mutated peptide and the template peptide APSYSPPPPP. In (D), the conformational entropy was included in the binding free energies.</p></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.g003" xlink:type="simple"/></fig><p>It should be noted that the preference of residue at P<sub>−5</sub> are closely related to the residues at the adjacent positions. For example, the known binder FGTYPPPLPP (A4 in <xref ref-type="table" rid="pcbi-0020001-t001">Table 1</xref>) has a Gly at P<sub>−5</sub>, which is not favored at this position based on the VM result. By analyzing the MD trajectory on A4-SH3 complex, we found that Phe at P<sub>−6</sub> in A4 can occupy the binding pocket that is occupied by Pro at P<sub>−5</sub> in the template peptide APSYSPPPPP to form favorable van der Waals interactions with Trp36 and Trp47. Moreover, the benzyl ring of Phe at P<sub>−6</sub> is parallel to the aromatic ring of Trp47 to form strong π-π stacking interactions. Therefore, if there is a small residue (Ala, Gly, or Ser) at P<sub>−5</sub>, an aromatic residue (Tyr, Phe, or Trp) may be preferred at P<sub>−6</sub>. This suggests that the repertoire of SH3 domain-binding peptides may be much larger than previously thought.</p><p>Our analysis showed that Trp, Phe, Tyr, Met, and Pro are favored at P<sub>−3</sub> (<xref ref-type="fig" rid="pcbi-0020001-g003">Figure 3</xref>B), which is in good agreement with the study of Villanueva's et al. that the most favorable residues are Trp, Tyr, Phe, and Met (ordered based on the binding free energies) [<xref ref-type="bibr" rid="pcbi-0020001-b022">22</xref>]. This observation is consistent with findings that an aromatic residue is favored at P<sub>−3</sub> of mouse protein 3BP1, a known binder of the Abl SH3 domain [<xref ref-type="bibr" rid="pcbi-0020001-b012">12</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b023">23</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b024">24</xref>]. The energy component analysis (<xref ref-type="supplementary-material" rid="pcbi-0020001-st004">Table S4</xref>) suggests that the strong preference of these four residues at this position is mainly due to the favorable non-polar contribution (ΔE<sub>vdw</sub> + ΔG<sub>SA</sub>) upon peptide binding: Δ<italic>E</italic><sub>vdw</sub> + Δ<italic>G</italic><sub>SA</sub> for Trp, Tyr, Met, and Phe are −55.9, −55.4, −54.4, and −53.8 kcal/mol, respectively, which are stronger than the other 16 residues at this position. Interestingly, positive charged residues, Arg and Lys, are not favored at this position, which is in contrast to most SH3 domain-binding peptides. To investigate the reason, we have compared the electrostatic surfaces of four SH3 domains, Abl tyrosine kinase SH3 domain (PDB entry 1bbz) [<xref ref-type="bibr" rid="pcbi-0020001-b025">25</xref>], c-Crk N-terminal SH3 domain (PDB entry 1cka) [<xref ref-type="bibr" rid="pcbi-0020001-b026">26</xref>], Grb2 N-terminal SH3 domain (PDB entry 1gbq) [<xref ref-type="bibr" rid="pcbi-0020001-b027">27</xref>], and rat amphiphysin-2 SH3 domain (PDB entry 1bb9) [<xref ref-type="bibr" rid="pcbi-0020001-b028">28</xref>] (<xref ref-type="fig" rid="pcbi-0020001-g004">Figure 4</xref>). Electrostatic potentials were calculated by solving the Poisson-Boltzmann equation using the Delphi program [<xref ref-type="bibr" rid="pcbi-0020001-b029">29</xref>] in Insight II [<xref ref-type="bibr" rid="pcbi-0020001-b030">30</xref>]. We find that the rat amphiphysin-2 SH3 domain has the largest areas of negative electrostatic potentials, which is mainly due to the acidic residues in Arg-Thr and extended n-Src loops of the domain. The large patch of negative electrostatic potential explains why the amphiphysin SH3 domain specifically recognizes the PXRPXR motif with two positively charged Arg residues. The c-Crk N-terminal and the Grb2 N-terminal SH3 domain have distinct but relatively small negative potential near the Arg-Thr and n-Src loop, which may explain why these two SH3 domains bind to peptides only possessing a single positively charged residue. Compared with the other three SH3 domains, the Abl SH3 domain does not possess remarkable and continuous distribution of the negative electrostatic potentials and therefore positively charged residues are not strongly preferred.</p><fig id="pcbi-0020001-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.g004</object-id><label>Figure 4</label><caption><title>The Electrostatic Potentials of the Peptide-Binding Interfaces for Four SH3 Domains</title><p>(A) 1bbz, (B) 1cka, (C) 1gbq, and (D) 1bb9.</p><p>The scale of gradation was from −5 kT/e to +5 kT/e corresponding to red color to blue color. The electrostatic potentials of proteins were calculated using the Delphi module in Insight II. The salt concentration was set to 0.0 M because electrostatic potentials had small changes in the range of the experimental salt concentrations. The internal and external dielectric constants were set to 1 and 80, respectively. Electrostatic potentials were computed using a grid space of 0.5 Å with the focusing technique. The structures of the four SH3 domains were aligned using the Homology module in Insight II. The Tyr residue at P<sub>−3</sub> in peptide APSYSPPPPP was shown in stick.</p></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.g004" xlink:type="simple"/></fig><p>Proline is highly preferred at positions P<sub>0</sub> and P<sub>3</sub>. We find that Pro at P<sub>0</sub> has favorable interactions with Phe9 and Tyr52 (−1.0 kcal/mol and −1.0 kcal/mol) (<xref ref-type="supplementary-material" rid="pcbi-0020001-st007">Table S7</xref>), as well as favorable van der Waals interaction with Pro49 (−0.8 kcal/mol). Experimental and theoretical studies have focused on understanding how SH3 domains recognize the core motif PXXP [<xref ref-type="bibr" rid="pcbi-0020001-b031">31</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b032">32</xref>]. Proline is the most favorable residue at this position based on our free energy calculation (<xref ref-type="fig" rid="pcbi-0020001-g003">Figure 3</xref>C). When only the non-polar contribution (Δ<italic>E</italic><sub>vdw</sub> + Δ<italic>G</italic><sub>SA</sub>) is considered, the peptide with Pro has the strongest interaction with SH3 (−54.8 kcal/mol) (<xref ref-type="supplementary-material" rid="pcbi-0020001-st005">Table S5</xref>), which agrees with the study of Wang et al. [<xref ref-type="bibr" rid="pcbi-0020001-b031">31</xref>]. In addition to the non-polar contribution, we found the less unfavorable desolvation-free energy is also an important factor for the preference of proline. For example, the residues at P<sub>0</sub> in peptides 16, 19, and 20 (<xref ref-type="supplementary-material" rid="pcbi-0020001-st005">Table S5</xref>) all have relatively small side chains (Thr, Val, and Pro, respectively) and have similar protein-ligand electrostatic interactions Δ<italic>E</italic><sub>ele</sub>. When the polar contributions of desolvation-free energies Δ<italic>G</italic><sub>PB</sub> were considered, the peptide 20 has the least unfavorable contribution (Δ<italic>E</italic><sub>ele</sub> + Δ<italic>G</italic><sub>PB</sub> = + 20.5 kcal/mol). We believe that upon peptide binding the desolvation cost for the nitrogen-substituted atom in Pro may be less than that of the non-substituted nitrogen atom in the other amino acids, because the non-substituted nitrogen atom can be easily polarized by the solvent [<xref ref-type="bibr" rid="pcbi-0020001-b032">32</xref>].</p><p>Proline is also strongly selected at P<sub>3</sub> in almost all SH3 domain-binding peptides. From the calculated binding free energies (<xref ref-type="fig" rid="pcbi-0020001-g003">Figure 3</xref>D), it is interesting to find that, although Pro is preferred at this position by the Abl SH3 domain, the preference is not very strong. Proline at this position can be mutated to several other residues including Trp, Phe, Met, His, Leu, Gln, and Tyr, and the mutated peptides still have relatively strong binding free energies. Our calculation seems to contrast with what has been suggested about the critical role of Pro at P<sub>3</sub> in SH3 ligands [<xref ref-type="bibr" rid="pcbi-0020001-b010">10</xref>]. However, in the mutation experiments reported by Pisabarro et al. [<xref ref-type="bibr" rid="pcbi-0020001-b017">17</xref>], Pro at P<sub>3</sub> in peptide APTYPPPLPP was mutated to His, Leu, and Tyr, and the binding affinities of the mutated peptides were only slightly decreased from −7.1 kcal/mol to −6.2, −6.2, and −6.2 kcal/mol, respectively. These three favorable residues reported by Pisabarro et al. were also relatively favored in our predictions.</p></sec></sec><sec id="s2b"><title>Identifying Physiological Interacting Partners of the Abl SH3 Domain</title><p>Based on the comparison between the experimental and calculated results, we have shown that the VM method can determine the binding motif of the Abl SH3 domain. The difference between the binding free energies of the mutated peptide at each position and the template peptide APSYSPPPPP, called SPMFEP, can be used as a position specific scoring matrix to predict the binding affinities of peptides (<xref ref-type="table" rid="pcbi-0020001-t002">Table 2</xref>). To evaluate the performance of SPMFEP, the 15 binders and 20 non-binders were first scored using SPMFEP. Two obvious distributions for binders and non-binders can be observed (<xref ref-type="fig" rid="pcbi-0020001-g005">Figure 5</xref>), indicating that binders and non-binders can be successfully distinguished by SPMFEP. The binding affinity of peptide A4 was under-estimated. From our analysis (see above), we know that Phe at P<sub>−6</sub> in the peptide A4 is favorable in the hydrophobic binding pocket that is originally occupied by Pro at P<sub>−5</sub> in the template peptide. Consequently, the residues at P<sub>−6</sub> and P<sub>−5</sub> may interact with each other. In SPMFEP, the inter-dependence between positions is not considered. In fact, all methods using a position specific scoring matrix, such as Scansite [<xref ref-type="bibr" rid="pcbi-0020001-b013">13</xref>], have the same limitations. Overall, SPMFEP performs well on the selected 35 peptides.</p><table-wrap content-type="2col" id="pcbi-0020001-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.t002</object-id><label>Table 2</label><caption><p>SPMFEPs of the Abl SH3 Domain</p></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.t002" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb1col1" align="left" charoff="0" char=""/><col id="tb1col2" align="left" charoff="0" char=""/><col id="tb1col3" align="char" charoff="0" char="."/><col id="tb1col4" align="char" charoff="0" char="."/><col id="tb1col5" align="char" charoff="0" char="."/><col id="tb1col6" align="char" charoff="0" char="."/><col id="tb1col7" align="char" charoff="0" char="."/><col id="tb1col8" align="char" charoff="0" char="."/><col id="tb1col9" align="char" charoff="0" char="."/><col id="tb1col10" align="char" charoff="0" char="."/><col id="tb1col11" align="char" charoff="0" char="."/><col id="tb1col12" align="char" charoff="0" char="."/><col id="tb1col13" align="char" charoff="0" char="."/></colgroup><thead><tr><td align="left"><hr/>Number</td><td><hr/>Sequence</td><td><hr/>&Delta;G<sub>exp</sub></td><td><hr/>&Delta;&Delta;G<sub>exp</sub></td><td><hr/>&Delta;<italic>E</italic><sub>ele</sub></td><td><hr/>&Delta;<italic>E</italic><sub>vdw</sub></td><td><hr/>&Delta;<italic>G</italic><sub>SA</sub></td><td><hr/>&Delta;<italic>G</italic><sub>PB</sub></td><td><hr/>T&Delta;S</td><td><hr/>G<sub>lig_bound</sub></td><td><hr/>G<sub>lig_unbound</sub></td><td><hr/>&Delta;G<sub>pred</sub><sup>a</sup></td><td><hr/>&Delta;&Delta;G<sub>pred</sub></td></tr></thead><tbody><tr><td>A1</td><td>APSYSPPPPP</td><td>&minus;7.94</td><td>0.00</td><td>&minus;92.0 &plusmn; 3.4</td><td>&minus;49.6 &plusmn; 0.4</td><td>&minus;5.3 &plusmn; 0.0</td><td>112.5 &plusmn; 2.9</td><td>&minus;31.2 &plusmn; 0.2</td><td>&minus;17.8 &plusmn; 0.6</td><td valign="middle">&minus;18.3 &plusmn; 1.5</td><td valign="middle">&minus;2.6 &plusmn; 0.8</td><td>0.0</td></tr><tr><td>A2</td><td>APTMPPPLPP</td><td>&minus;6.17</td><td>1.77</td><td>&minus;71.4 &plusmn; 4.9</td><td>&minus;49.5 &plusmn; 0.4</td><td>&minus;5.4 &plusmn; 0.1</td><td>92.7 &plusmn; 5.1</td><td>&minus;33.6 &plusmn; 0.3</td><td>&minus;33.2 &plusmn; 0.8</td><td valign="middle">&minus;36.2 &plusmn; 0.9</td><td valign="middle">2.9 &plusmn; 0.2</td><td>5.5</td></tr><tr><td>A3</td><td>PPAYPPPPVP</td><td>&minus;7.23</td><td>0.71</td><td>&minus;83.2 &plusmn; 3.6</td><td>&minus;50.8 &plusmn; 0.5</td><td>&minus;5.4 &plusmn; 0.0</td><td>101.5 &plusmn; 2.6</td><td>&minus;31.8 &plusmn; 0.1</td><td>85.5 &plusmn; 0.7</td><td valign="middle">83.9 &plusmn; 0.3</td><td valign="middle">&minus;4.5 &plusmn; 1.0</td><td>&minus;1.9</td></tr><tr><td>A4</td><td>FGTYPPPLPP</td><td>&minus;7.03</td><td>0.91</td><td>&minus;70.3 &plusmn; 7.3</td><td>&minus;49.9 &plusmn; 0.2</td><td>&minus;5.6 &plusmn; 0.0</td><td>89.7 &plusmn; 7.6</td><td>&minus;33.0 &plusmn; 0.3</td><td>&minus;41.8 &plusmn; 0.4</td><td valign="middle">&minus;42.2 &plusmn; 1.3</td><td valign="middle">&minus;2.6 &plusmn; 0.5</td><td>&minus;0.1</td></tr><tr><td>A5</td><td>SPSYSPPPPP</td><td>&minus;7.83</td><td>0.11</td><td>&minus;100.0 &plusmn; 3.6</td><td>&minus;48.2 &plusmn; 1.0</td><td>&minus;5.2 &plusmn; 0.0</td><td>119.4 &plusmn; 2.8</td><td>&minus;31.9 &plusmn; 0.1</td><td>&minus;43.6 &plusmn; 1.1</td><td valign="middle">&minus;43.0 &plusmn; 0.9</td><td>&minus;3.0 &plusmn; 0.8</td><td>&minus;0.4</td></tr><tr><td>A6</td><td>APTYSPPPPP</td><td>&minus;8.72</td><td>&minus;0.78</td><td>&minus;103.2 &plusmn; 18.9</td><td>&minus;50.2 &plusmn; 1.6</td><td>&minus;5.4 &plusmn; 0.1</td><td>122.0 &plusmn; 16.4</td><td>&minus;31.1 &plusmn; 0.4</td><td>&minus;53.9 &plusmn; 1.7</td><td valign="middle">&minus;55.7 &plusmn; 0.8</td><td valign="middle">&minus;4.0 &plusmn; 1.6</td><td>&minus;1.4</td></tr><tr><td>A7</td><td>APTMSPPLPP</td><td>&minus;6.37</td><td>1.57</td><td>&minus;80.8 &plusmn; 8.3</td><td>&minus;50.6 &plusmn; 0.8</td><td>&minus;5.3 &plusmn; 0.0</td><td>103.5 &plusmn; 9.0</td><td>&minus;33.8 &plusmn; 0.3</td><td>&minus;63.9 &plusmn; 2.9</td><td valign="middle">&minus;64.7 &plusmn; 2.6</td><td valign="middle">1.5 &plusmn; 0.6</td><td>4.0</td></tr><tr><td>A8</td><td>APTYPPPLNP</td><td>&minus;5.48</td><td>2.46</td><td>&minus;97.6 &plusmn; 8.0</td><td>&minus;51.3 &plusmn; 0.5</td><td>&minus;5.5 &plusmn; 0.0</td><td>118.7 &plusmn; 6.7</td><td>&minus;31.6 &plusmn; 0.4</td><td>&minus;90.4 &plusmn; 1.6</td><td valign="middle">&minus;95.2 &plusmn; 0.1</td><td valign="middle">0.8 &plusmn; 1.3</td><td>3.4</td></tr><tr><td>A9</td><td>APTYHPPLPP</td><td>&minus;5.30</td><td>2.64</td><td>&minus;75.2 &plusmn; 1.4</td><td>&minus;51.2 &plusmn; 0.5</td><td>&minus;5.4 &plusmn; 0.0</td><td>99.4 &plusmn; 1.5</td><td>&minus;30.9 &plusmn; 0.1</td><td>&minus;28.3 &plusmn; 2.2</td><td valign="middle">&minus;32.7 &plusmn; 1.4</td><td valign="middle">2.9 &plusmn; 0.7</td><td>5.5</td></tr><tr><td>A10</td><td>APTMPPPPPP</td><td>&minus;6.95</td><td>0.99</td><td>&minus;80.8 &plusmn; 5.0</td><td>&minus;48.9 &plusmn; 0.6</td><td>&minus;5.3 &plusmn; 0.0</td><td>99.6 &plusmn; 4.9</td><td>&minus;33.4 &plusmn; 0.4</td><td>&minus;33.8 &plusmn; 1.6</td><td valign="middle">&minus;34.1 &plusmn; 0.2</td><td valign="middle">&minus;1.8 &plusmn; 0.6</td><td>0.8</td></tr><tr><td>A11</td><td>APTYPPPLPH</td><td>&minus;6.23</td><td>1.71</td><td>&minus;83.7 &plusmn; 4.2</td><td>&minus;53.6 &plusmn; 0.7</td><td>&minus;5.7 &plusmn; 0.0</td><td>107.4 &plusmn; 3.6</td><td>&minus;32.0 &plusmn; 0.2</td><td>&minus;39.7 &plusmn; 3.6</td><td valign="middle">&minus;45.3 &plusmn; 0.9</td><td valign="middle">2.0 &plusmn; 0.8</td><td>4.6</td></tr><tr><td>A12</td><td>APTYPPPLPL</td><td>&minus;6.17</td><td>1.77</td><td>&minus;87.7 &plusmn; 6.7</td><td>&minus;51.8 &plusmn; 0.4</td><td>&minus;5.5 &plusmn; 0.1</td><td>112.2 &plusmn; 6.2</td><td>&minus;31.3 &plusmn; 0.4</td><td>&minus;62.3 &plusmn; 2.1</td><td valign="middle">&minus;65.8 &plusmn; 0.3</td><td valign="middle">1.9 &plusmn; 0.1</td><td>4.4</td></tr><tr><td>A13</td><td>APTYPPPPPP</td><td>&minus;7.36</td><td>0.58</td><td>&minus;93.8 &plusmn; 7.2</td><td>&minus;50.2 &plusmn; 0.5</td><td>&minus;5.3 &plusmn; 0.1</td><td>113.4 &plusmn; 6.9</td><td>&minus;31.4 &plusmn; 0.2</td><td>&minus;31.8 &plusmn; 0.9</td><td valign="middle">&minus;31.8 &plusmn; 1.3</td><td valign="middle">&minus;4.5 &plusmn; 0.3</td><td>&minus;2.0</td></tr><tr><td>A14</td><td>APTYSPPLPP</td><td>&minus;7.23</td><td>0.71</td><td>&minus;90.1 &plusmn; 9.6</td><td>&minus;51.2 &plusmn; 0.3</td><td>&minus;5.5 &plusmn; 0.1</td><td>112.2 &plusmn; 9.6</td><td>&minus;32.2 &plusmn; 0.0</td><td>&minus;56.7 &plusmn; 1.2</td><td valign="middle">&minus;59.5 &plusmn; 1.1</td><td valign="middle">0.5 &plusmn; 0.3</td><td>3.1</td></tr><tr><td>A15</td><td>ALPYPPPLPP</td><td>&minus;5.93</td><td>2.01</td><td>&minus;95.1 &plusmn; 1.2</td><td>&minus;45.7 &plusmn; 0.1</td><td>&minus;5.1 &plusmn; 0.0</td><td>116.5 &plusmn; 1.8</td><td>&minus;32.9 &plusmn; 0.4</td><td>24.3 &plusmn; 0.9</td><td valign="middle">24.9 &plusmn; 1.8</td><td valign="middle">2.6 &plusmn; 0.8</td><td>5.2</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt101"><p>&Delta;&Delta;<italic>G</italic><sub>exp</sub> is the difference between the experimental binding free energies of each peptide and the template peptide APSYSPPPPP; &Delta;<italic>E</italic><sub>ele</sub> and &Delta;<italic>E</italic><sub>vdw</sub> are the electrostatic interaction and van der Waals interaction between the peptide and the Abl SH3 domain, respectively; &Delta;<italic>G</italic><sub>SA</sub> and &Delta;<italic>G</italic><sub>PB</sub> are the non-polar and polar contributions of the solvation free energy upon peptide binding, respectively; <italic>G</italic><sub>lig_bound</sub> and <italic>G</italic><sub>lig_unbound</sub> are the conformational energy of peptide in the bound and un-bound states, respectively; &Delta;<italic>G</italic><sub>pred</sub> is the predicted binding free energy; &Delta;&Delta;<italic>G</italic><sub>pred</sub> is the difference between the predicted binding free energy of each peptide and the template peptide APSYSPPPPP.</p></fn><fn id="nt102"><p><sup>a</sup>Standard deviations are estimated from three block average values.</p></fn></table-wrap-foot> --></table-wrap><fig id="pcbi-0020001-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.g005</object-id><label>Figure 5</label><caption><title>The Distribution of the Predicted Binding Free Energies Based on SPMFEP for Binders and Non-Binders</title></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.g005" xlink:type="simple"/></fig><p>We next scanned the SWISS-PROT using SPMFEP to predict interacting partners of the Abl SH3 domain. There are about 6.2 × 10<sup>7</sup> ten-residue-long peptides in the current SWISS-PROT database (May 2005), in which about 218,540 ten-residue-long peptides have the PXXP motif. Only about 2,600 peptides have scores smaller than two, which are in the top 0.005% (the top 600 peptide sequences in 353 unique human proteins are listed in <xref ref-type="supplementary-material" rid="pcbi-0020001-st009">Table S9</xref>). We first carefully examined the top ten candidates in the human proteome (<xref ref-type="table" rid="pcbi-0020001-t003">Table 3</xref>), among which WASF1 and EVL are known interacting partners of the Abl SH3 domain [<xref ref-type="bibr" rid="pcbi-0020001-b033">33</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b034">34</xref>]. WASF4 is a homology of WASF1 and is in the same protein family. SEM6A is a homology of the mouse protein SEM6D, a known Abl SH3 domain-binding protein, and is therefore likely to be a true binder [<xref ref-type="bibr" rid="pcbi-0020001-b035">35</xref>]. In total, we have identified two known binders and two candidates highly supported by experimental evidence, among the top ten peptides, which is a surprisingly good result. As a comparison, the top ten human peptides in the Scansite search are [<xref ref-type="bibr" rid="pcbi-0020001-b013">13</xref>] 3BP2, RX, RBMG, TACT, PRL3, SCA3, AT19, AD08, DYN2, and SEP4, among which only 3BP2, the homology of a known binder (mouse protein 3BP2), is likely to be a true binder [<xref ref-type="bibr" rid="pcbi-0020001-b036">36</xref>] but no binding information is found for all other candidates in BIND [<xref ref-type="bibr" rid="pcbi-0020001-b036">36</xref>] and MINT [<xref ref-type="bibr" rid="pcbi-0020001-b037">37</xref>] databases to interact with Abl protein or the Abl SH3 domain. If only considering the top ten candidates, the SPMFEP method based on VM performs better than Scansite on identifying the interacting partners of the Abl SH3 domain.</p><table-wrap content-type="2col" id="pcbi-0020001-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.t003</object-id><label>Table 3</label><caption><p>Top Ten Binding Partner Candidates of the Abl SH3 Domain Identified by SPMFEP</p></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.t003" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb2col1" align="left" charoff="0" char=""/><col id="tb2col2" align="char" charoff="0" char="."/><col id="tb2col3" align="char" charoff="0" char="."/><col id="tb2col4" align="char" charoff="0" char="."/><col id="tb2col5" align="char" charoff="0" char="."/><col id="tb2col6" align="char" charoff="0" char="."/><col id="tb2col7" align="char" charoff="0" char="."/><col id="tb2col8" align="char" charoff="0" char="."/><col id="tb2col9" align="char" charoff="0" char="."/><col id="tb2col10" align="char" charoff="0" char="."/><col id="tb2col11" align="char" charoff="0" char="."/></colgroup><thead><tr><td align="left" valign="top">Residue</td><td colspan="10" valign="middle"><hr/>Position</td></tr><tr><td valign="middle"><hr/></td><td valign="middle"><hr/>P<sub>&minus;6</sub><sup>a</sup></td><td valign="middle"><hr/>P<sub>&minus;5</sub></td><td valign="middle"><hr/>P<sub>&minus;4</sub></td><td valign="middle"><hr/>P<sub>&minus;3</sub></td><td valign="middle"><hr/>P<sub>&minus;2</sub></td><td valign="middle"><hr/>P<sub>&minus;1</sub></td><td valign="middle"><hr/>P<sub>0</sub></td><td valign="middle"><hr/>P<sub>1</sub></td><td valign="middle"><hr/>P<sub>2</sub></td><td valign="middle"><hr/>P<sub>3</sub></td></tr></thead><tbody><tr><td valign="middle">A</td><td valign="middle">0.0</td><td valign="middle">6.4</td><td valign="middle">0.0</td><td valign="middle">6.7</td><td valign="middle">0.0</td><td valign="middle">5.4</td><td valign="middle">6.3</td><td valign="middle">&minus;0.4</td><td valign="middle">2.6</td><td valign="middle">1.8</td></tr><tr><td valign="middle">R</td><td valign="middle">4.0</td><td valign="middle">7.4</td><td valign="middle">13.6</td><td valign="middle">9.1</td><td valign="middle">3.50</td><td valign="middle">7.4</td><td valign="middle">17.2</td><td valign="middle">8.6</td><td valign="middle">8.8</td><td valign="middle">15.0</td></tr><tr><td valign="middle">N</td><td valign="middle">2.0</td><td valign="middle">2.9</td><td valign="middle">1.4</td><td valign="middle">2.3</td><td valign="middle">0.8</td><td valign="middle">5.2</td><td valign="middle">6.2</td><td valign="middle">6.6</td><td valign="middle">5.0</td><td valign="middle">3.3</td></tr><tr><td valign="middle">D</td><td valign="middle">4.0</td><td valign="middle">20.9</td><td valign="middle">4.2</td><td valign="middle">16.4</td><td valign="middle">12.3</td><td valign="middle">18.8</td><td valign="middle">11.4</td><td valign="middle">&minus;0.5</td><td valign="middle">2.3</td><td valign="middle">15.0</td></tr><tr><td valign="middle">C</td><td valign="middle">0.0</td><td valign="middle">4.4</td><td valign="middle">&minus;0.4</td><td valign="middle">1.6</td><td valign="middle">&minus;0.5</td><td valign="middle">3.4</td><td valign="middle">6.3</td><td valign="middle">&minus;0.1</td><td valign="middle">1.9</td><td valign="middle">3.5</td></tr><tr><td valign="middle">Q</td><td valign="middle">0.0</td><td valign="middle">18.4</td><td valign="middle">0.7</td><td valign="middle">3.3</td><td valign="middle">13.6</td><td valign="middle">2.8</td><td valign="middle">11.3</td><td valign="middle">1.2</td><td valign="middle">1.3</td><td valign="middle">1.3</td></tr><tr><td valign="middle">E</td><td valign="middle">4.0</td><td valign="middle">20.7</td><td valign="middle">8.6</td><td valign="middle">12.0</td><td valign="middle">13.7</td><td valign="middle">27.1</td><td valign="middle">14.2</td><td valign="middle">6.6</td><td valign="middle">6.6</td><td valign="middle">10.7</td></tr><tr><td valign="middle">G</td><td valign="middle">0.0</td><td valign="middle">9.3</td><td valign="middle">0.2</td><td valign="middle">3.3</td><td valign="middle">0.6</td><td valign="middle">7.7</td><td valign="middle">6.2</td><td valign="middle">0.9</td><td valign="middle">6.6</td><td valign="middle">11.6</td></tr><tr><td valign="middle">H</td><td valign="middle">0.0</td><td valign="middle">10.7</td><td valign="middle">1.1</td><td valign="middle">3.3</td><td valign="middle">0.7</td><td valign="middle">5.2</td><td valign="middle">4.0</td><td valign="middle">1.9</td><td valign="middle">6.5</td><td valign="middle">1.4</td></tr><tr><td valign="middle">I</td><td valign="middle">0.0</td><td valign="middle">10.8</td><td valign="middle">1.1</td><td valign="middle">1.5</td><td valign="middle">4.3</td><td valign="middle">6.2</td><td valign="middle">6.9</td><td valign="middle">5.4</td><td valign="middle">0.3</td><td valign="middle">5.5</td></tr><tr><td valign="middle">L</td><td valign="middle">0.0</td><td valign="middle">3.5</td><td valign="middle">1.6</td><td valign="middle">1.5</td><td valign="middle">7.6</td><td valign="middle">6.1</td><td valign="middle">7.5</td><td valign="middle">1.0</td><td valign="middle">1.4</td><td valign="middle">3.0</td></tr><tr><td valign="middle">K</td><td valign="middle">4.0</td><td valign="middle">5.3</td><td valign="middle">11.4</td><td valign="middle">9.1</td><td valign="middle">8.1</td><td valign="middle">5.6</td><td valign="middle">21.0</td><td valign="middle">8.6</td><td valign="middle">13.7</td><td valign="middle">15.2</td></tr><tr><td valign="middle">M</td><td valign="middle">0.0</td><td valign="middle">3.3</td><td valign="middle">3.3</td><td valign="middle">0.3</td><td valign="middle">3.1</td><td valign="middle">6.4</td><td valign="middle">4.0</td><td valign="middle">3.8</td><td valign="middle">0.8</td><td valign="middle">0.5</td></tr><tr><td valign="middle">F</td><td valign="middle">0.0</td><td valign="middle">3.3</td><td valign="middle">2.7</td><td valign="middle">&minus;1.5</td><td valign="middle">8.6</td><td valign="middle">7.3</td><td valign="middle">7.6</td><td valign="middle">5.4</td><td valign="middle">0.8</td><td valign="middle">0.7</td></tr><tr><td valign="middle">S</td><td valign="middle">0.0</td><td valign="middle">8.8</td><td valign="middle">1.1</td><td valign="middle">5.0</td><td valign="middle">0.1</td><td valign="middle">&minus;3.3</td><td valign="middle">9.4</td><td valign="middle">&minus;1.5</td><td valign="middle">5.3</td><td valign="middle">6.5</td></tr><tr><td valign="middle">T</td><td valign="middle">0.0</td><td valign="middle">5.2</td><td valign="middle">&minus;0.2</td><td valign="middle">3.5</td><td valign="middle">&minus;0.9</td><td valign="middle">7.5</td><td valign="middle">4.6</td><td valign="middle">1.0</td><td valign="middle">2.3</td><td valign="middle">5.2</td></tr><tr><td valign="middle">W</td><td valign="middle">0.0</td><td valign="middle">13.6</td><td valign="middle">0.1</td><td valign="middle">&minus;2.1</td><td valign="middle">7.4</td><td valign="middle">3.6</td><td valign="middle">1.4</td><td valign="middle">1.9</td><td valign="middle">1.6</td><td valign="middle">1.6</td></tr><tr><td valign="middle">Y</td><td valign="middle">0.0</td><td valign="middle">3.4</td><td valign="middle">4.0</td><td valign="middle">0.0</td><td valign="middle">3.4</td><td valign="middle">&minus;2.4</td><td valign="middle">5.8</td><td valign="middle">4.0</td><td valign="middle">1.4</td><td valign="middle">2.5</td></tr><tr><td valign="middle">V</td><td valign="middle">0.0</td><td valign="middle">2.0</td><td valign="middle">0.5</td><td valign="middle">3.3</td><td valign="middle">2.4</td><td valign="middle">&minus;2.8</td><td valign="middle">8.5</td><td valign="middle">&minus;0.2</td><td valign="middle">1.7</td><td valign="middle">3.8</td></tr><tr><td valign="middle">P</td><td valign="middle">0.0</td><td valign="middle">0.0</td><td valign="middle">&minus;0.6</td><td valign="middle">0.9</td><td valign="middle">&minus;0.2</td><td valign="middle">0.0</td><td valign="middle">0.0</td><td valign="middle">0.0</td><td valign="middle">0.0</td><td valign="middle">0.0</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt201"><p><sup>a</sup>Given the conformational flexibility of the terminal residue at P<sub>&minus;6</sub>, heuristic penalty scores were assigned: 4.0 to the most unfavorable residues R, D, E, K at P<sub>&minus;6,</sub> 2.0 to N, and 0 to other residues.</p></fn></table-wrap-foot> --></table-wrap><p>In MINT [<xref ref-type="bibr" rid="pcbi-0020001-b037">37</xref>] and BIND [<xref ref-type="bibr" rid="pcbi-0020001-b036">36</xref>], 44 non-redundant proteins have been identified to directly interact with the protein Abl, and 13 of them, including five mouse proteins and eight human proteins, bind to the Abl SH3 domain. We compared the performance of SPMFEP, Scansite [<xref ref-type="bibr" rid="pcbi-0020001-b013">13</xref>], and iSPOT [<xref ref-type="bibr" rid="pcbi-0020001-b014">14</xref>], to identify these 13 proteins (<xref ref-type="table" rid="pcbi-0020001-t004">Table 4</xref>). The top 600 candidates found in human proteins and the top 2,000 candidates found in all proteins were saved for further analyses.</p><table-wrap content-type="2col" id="pcbi-0020001-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.0020001.t004</object-id><label>Table 4</label><caption><p>Comparison of Predictions of SPMFEP, Scansite, and iSPOT on 13 Known Interacting Proteins of the Abl SH3 Domain</p></caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.t004" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb3col1" align="char" charoff="0" char="."/><col id="tb3col2" align="left" charoff="0" char=""/><col id="tb3col3" align="left" charoff="0" char=""/><col id="tb3col4" align="char" charoff="0" char="."/><col id="tb3col5" align="char" charoff="0" char="."/><col id="tb3col6" align="left" charoff="0" char=""/><col id="tb3col7" align="char" charoff="0" char="."/><col id="tb3col8" align="left" charoff="0" char=""/><col id="tb3col9" align="left" charoff="0" char=""/></colgroup><thead><tr><td align="left"><hr/>Rank</td><td><hr/>Protein</td><td><hr/>Accession ID</td><td><hr/>Start</td><td><hr/>End</td><td><hr/>Peptide</td><td><hr/>Score</td><td><hr/>Scansite Rank<sup>a</sup></td><td><hr/>Protein</td></tr></thead><tbody><tr><td>1</td><td>RW1</td><td>Q92545</td><td>1521</td><td>1530</td><td>SPTPASPSPP</td><td>&minus;4.1</td><td>&times;<sup>b</sup></td><td>RW1 protein &lsqb;fragment&rsqb;</td></tr><tr><td>2</td><td>WASF4 (SCAR2)</td><td>Q8IV90</td><td>475</td><td>484</td><td>PPPPSSPSFP</td><td>&minus;3.6</td><td>&times;<sup>b</sup></td><td>Wiskott-Aldrich syndrome protein family member 4</td></tr><tr><td>3</td><td>TREX1</td><td>Q9NSU2</td><td>107</td><td>116</td><td>GPPPTVPPPP</td><td>&minus;3.4</td><td>1,194</td><td>Three prime repair exonuclease 1</td></tr><tr><td>4</td><td>ACRO (ACR, ACRS)</td><td>P10323</td><td>344</td><td>353</td><td>PPPPPSPPPP</td><td>&minus;3.2</td><td>54</td><td>Acrosin &lsqb;precursor&rsqb;</td></tr><tr><td>5</td><td>LRRN5 (GAC1)</td><td>O75325</td><td>22</td><td>31</td><td>VVPWHVPCPP</td><td>&minus;2.9</td><td>&times;<sup>b</sup></td><td>Leucine-rich repeats neuronal protein 5 &lsqb;precursor&rsqb;</td></tr><tr><td>6</td><td>SEM6A (SEMA6A)</td><td>Q9H2E6</td><td>791</td><td>800</td><td>MPPMGSPVIP</td><td>&minus;2.9</td><td>&times;<sup>b</sup></td><td>Semaphorin 6A &lsqb;precursor&rsqb;</td></tr><tr><td>7</td><td>HDAC4 (HD4)</td><td>P56524</td><td>343</td><td>352</td><td>LPLYTSPSLP</td><td>&minus;2.8</td><td>&times;<sup>b</sup></td><td>Histone deacetylase 4</td></tr><tr><td>8</td><td>EVL (RNB6)</td><td>Q9UI08</td><td>185</td><td>194</td><td>PPPPPVPPPP</td><td>&minus;2.7</td><td>83</td><td>Ena/vasodilator stimulated phosphoprotein-like protein</td></tr><tr><td>9</td><td>WASF1 (WAVE1, WAVE-1)</td><td>Q92558</td><td>347</td><td>356</td><td>TPPPPVPPPP</td><td>&minus;2.7</td><td>132</td><td>Wiskott-Aldrich syndrome protein family member 1</td></tr><tr><td>10</td><td>YLPM1 (ZAP3, ZAP113)</td><td>P49750</td><td>14</td><td>23</td><td>YPPPPVPPPP</td><td>&minus;2.7</td><td>115</td><td>YLP motif containing protein 1</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt301"><p><sup>a</sup>Only the top 2,000 candidate peptides are shown in the Scansite Web site.</p></fn><fn id="nt302"><p><sup>b</sup>&times; represents not in the top 2,000 peptide list.</p></fn><fn id="nt303"><p>DOI: 10..1371/journal.pcbi.0020001.t003</p></fn></table-wrap-foot> --></table-wrap><p>SPMFEP can successfully identify ten known binders: seven of the eight human proteins and three of the five mouse proteins (<xref ref-type="table" rid="pcbi-0020001-t004">Table 4</xref> and <xref ref-type="supplementary-material" rid="pcbi-0020001-st008">Table S8</xref>). 3BP1_mouse and 3BP2_mouse are not ranked highly, considering all proteins (1,393 and 1,895) but they are in the top 500 if only mouse proteins are considered. The human homologies of 3BP1_mouse and 3BP2_mouse are in the top 600 candidates (249 for 3BP1_human and 502 for 3BP2_human) (<xref ref-type="supplementary-material" rid="pcbi-0020001-st009">Table S9</xref>) and it is reasonable to believe that they are true binders of the Abl SH3 domain. Overall, we have successfully identified most of the known binders of the Abl SH3 domain.</p><p>Scansite can identify eight known binders of the Abl SH3 domain (<xref ref-type="table" rid="pcbi-0020001-t004">Table 4</xref>). P73_human, not identified by SPMFEP, is ranked 321 in the Scansite result. Agami et al. [<xref ref-type="bibr" rid="pcbi-0020001-b038">38</xref>] reported that a P73 mutant P338A could not form stable P73-Abl complexes. If P73 interacts with Abl by ten-residue-long peptide segment, this peptide segment should be AFKQSPPAVP, which is the same as the peptide identified by Scansite. Based on our VM analysis and mutation experiments by Pisabarro and Serrano [<xref ref-type="bibr" rid="pcbi-0020001-b017">17</xref>], Phe at P<sub>−5</sub> and Lys at P<sub>−4</sub> are not favored. Because Scansite considers 15-residue-long peptides rather than ten-residue-long peptides in SPMFEP, it is likely that the five additional residues may contribute favorably to binding. It is not surprising that the longer the peptide, the more specific, but less sensitive, are the predictions.</p><p>Using iSPOT, we can only correctly identify five binders (<xref ref-type="table" rid="pcbi-0020001-t004">Table 4</xref>). In iSPOT, the scoring matrix was derived from position-specific contacts based on six SH3-peptide or SH3-protein complex structures [<xref ref-type="bibr" rid="pcbi-0020001-b014">14</xref>]. The accuracy of the matrix is limited by the relatively small number of residue-resident contacts found between SH3 domains and their binding peptides to fill the 27 × 10 × 10 × 10 position-specific contact matrix.</p><p>CABL2_human and SEM6D_mouse (<xref ref-type="table" rid="pcbi-0020001-t004">Table 4</xref>) cannot be identified by all the three methods. Experiments [<xref ref-type="bibr" rid="pcbi-0020001-b035">35</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b039">39</xref>] have shown that their interactions with Abl are mediated by the interaction between the proline-rich region and the Abl SH3 domain. Since the scoring matrix used by all the three methods does not consider dependence between positions, we suspect that synergistic interactions may exist between positions within or beyond the proline-rich regions of the two proteins.</p></sec></sec><sec id="s3"><title>Discussion</title><p>In this study, we have demonstrated that the MM/PBSA method can accurately calculate the binding free energies between the Abl SH3 domain and its peptide ligands. Examination of each component of the binding free energy shows that, besides the non-bonded interactions and desolvation effect, the change of the conformational energies of the peptides upon binding is also crucial to determine the binding specificity of the domain. These results are encouraging to apply MD simulation and free energy calculation to understand the molecular mechanism of other domain-peptide and protein-protein interactions.</p><p>We have also shown that the VM method can precisely determine the sequence motif recognized by the Abl SH3 domain. The experimental scheme of the VM method is totally different from those of the current peptide library experiments in the following ways: 1) produce all possible peptides that are one amino acid different from the template peptide; (2) measure the “binding” affinities of all these peptides; and, (3) generate a scoring matrix based on the binding affinity differences between the mutated and the template peptides to determine the binding motif.</p><p>There are advantages of this scheme. First, the preference of an amino acid is quantitatively measured, based on the binding affinity of the peptide, which at least partially overcomes the sampling difficulty in the current peptide library experiment. Ideally, to determine the binding motif of a domain, one should examine the binding between the domain and all possible peptides of a given length, and align all binding peptides to calculate the frequency of each amino acid occurring at each position. In reality, there are usually only 10<sup>7</sup>–10<sup>10</sup> peptides in the library, due to the limit of time and cost. If the length of the binding peptide is ten, there are 10<sup>10</sup>–10<sup>13</sup> possible peptides and the coverage of the peptide sequence space by the peptide library is about 10<sup>−6</sup>–10<sup>−3</sup>. If 15-residue-long peptides are considered as in Scansite, the coverage drops dramatically to 10<sup>−12</sup>–10<sup>−9</sup>. By measuring the relative preference of every amino acid based on the peptide-binding affinities, one overcomes this insufficient sampling issue and mimics the ideal procedure given the position-independence assumption. Second, the VM method can evaluate the penalties of unfavorable amino acids even the peptide do not really bind to the protein, which is very hard if not impossible in the experimental approaches. Third, since the scoring matrix is obtained by taking the difference between the template and the mutated peptides that are only one amino acid different from the template peptide, some errors due to insufficient sampling of conformational space and/or inaccurate free energy calculation can be cancelled.</p><p>There are two major hurdles of applying the VM method in a high-throughput manner. First, the MD simulation and free energy calculations are time-consuming. Second, a domain-peptide complex structure is required. Given the fast pace of advancement of computer power and structural genomics/homology modeling, we believe that the VM method will become more and more useful.</p></sec><sec id="s4"><title>Materials and Methods</title><sec id="s4a"><title>MD simulations.</title><p>MD simulations were performed on the 15 binders and 20 non-binders of the Abl SH3 domain using the AMBER 8 simulation package [<xref ref-type="bibr" rid="pcbi-0020001-b019">19</xref>] and AMBER03 force field [<xref ref-type="bibr" rid="pcbi-0020001-b040">40</xref>]. The amino acid sequences and the experimentally determined binding affinities of the 15 binders are shown in <xref ref-type="table" rid="pcbi-0020001-t001">Table 1</xref> [<xref ref-type="bibr" rid="pcbi-0020001-b017">17</xref>]. Ten peptides, B1 to B10, were randomly selected from the human proteome and are considered as non-binders (<xref ref-type="supplementary-material" rid="pcbi-0020001-st001">Table S1</xref>). Ten peptides, C1 to C10, do not bind to the Abl SH3 domain but are Class I binders of other SH3 domains [<xref ref-type="bibr" rid="pcbi-0020001-b012">12</xref>]: C1 and C2 bind to the Src SH3 domains, C3 and C4 bind to the Yes SH3 domain, and C5 to C10 bind to the Grb2 N-terminal SH3 domain (<xref ref-type="supplementary-material" rid="pcbi-0020001-st001">Table S1</xref>). We chose the crystal structure of the peptide APSYSPPPPP complexed with the Abl SH3 domain (Class I binder and the PDB entry is 1bbz) [<xref ref-type="bibr" rid="pcbi-0020001-b025">25</xref>] as the template and mutated it to other peptides using the <italic>scap</italic> program [<xref ref-type="bibr" rid="pcbi-0020001-b041">41</xref>]. The complex was solvated in a rectangular box of about 3,000 TIP3P water molecules so that the boundary of the box is at least 9 Å away from any solute atom. Counter-ions of Na<sup>+</sup> were placed based on the Columbic potential to keep the whole system neutral. Particle Mesh Ewald (PME) was employed to consider the long-range electrostatic interactions [<xref ref-type="bibr" rid="pcbi-0020001-b042">42</xref>]. Following 2,000 steps of minimization, a 1.2 ns (30 ps temperature increase from 10 °K to 300 °K and 1.17 ns equilibration and data collection) MD simulation with a 2.0 fs time step was performed on each complex. The SHAKE procedure was employed to constrain hydrogen atoms [<xref ref-type="bibr" rid="pcbi-0020001-b043">43</xref>] during MD and all heavy atoms of SH3 were restrained using a 5 kcal·mol<sup>−1</sup>·Å<sup>−2</sup> harmonic force (see <xref ref-type="sec" rid="s3">discussion</xref> in Supporting Information).</p><p>To determine the conformational energy of unbound peptide in solvent, 2.0 ns MD simulation was conducted on each peptide. Each peptide was solvated in a water box of about 1,600 water molecules, which extended 10 Å away from any peptide atom. 1,000 steps of minimization were followed by a 2.0 ns MD simulation for equilibration and data collection using the same set-up as described above.</p></sec><sec id="s4b"><title>Free energy calculations using the MM/PBSA method.</title><p>The binding free energy is calculated as:</p><disp-formula id="pcbi-0020001-e001"><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.e001" xlink:type="simple"/><!-- <table frame="hsides" rules="none"><colgroup><col id="tb4col1" align="left" charoff="0" char=""/><col id="2" align="left" charoff="0" char=""/><col id="3" align="left" charoff="0" char=""/><col id="4" align="left" charoff="0" char=""/><col id="5" align="left" charoff="0" char=""/><col id="6" align="left" charoff="0" char=""/></colgroup><thead><tr><td align="left"><hr/>Protein</td><td><hr/>Accession ID</td><td><hr/>SPMFEP</td><td><hr/>Scansite</td><td><hr/>iSPOT</td><td><hr/>Description</td></tr></thead><tbody><tr><td>3BP1_mouse &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b045">45</xref>&rsqb;</td><td>P55194</td><td>&radic;</td><td>&times;</td><td>&times;</td><td>SH3 domain-binding protein 1</td></tr><tr><td>3BP2_mouse &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b046">46</xref>&rsqb;</td><td>Q06649</td><td>&radic;</td><td>&radic;</td><td>&radic;</td><td>SH3 domain-binding protein 2</td></tr><tr><td>EVL_human &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b035">35</xref>&rsqb;</td><td>Q9UI08</td><td>&radic;</td><td>&radic;</td><td>&radic;</td><td>Ena/vasodilator stimulated phosphoprotein-like protein (Ena/VASP-like protein)</td></tr><tr><td>NMDE4_human &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b047">47</xref>&rsqb;</td><td>O15399</td><td>&radic;</td><td>&radic;</td><td>&times;</td><td>Glutamate &lsqb;NMDA&rsqb; receptor subunit epsilon 4</td></tr><tr><td>P73_human &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b038">38</xref>&rsqb;</td><td>O15350</td><td>&times;</td><td>&radic;</td><td>&times;</td><td>Tumor protein p73 (p53-like transcription factor) (p53-related protein)</td></tr><tr><td>PLS1_human &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b045">45</xref>&rsqb;</td><td>O15162</td><td>&radic;</td><td>&times;</td><td>&times;</td><td>Phospholipid scramblase 1, type II membrane protein</td></tr><tr><td>WASF1_human &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b033">33</xref>&rsqb;</td><td>Q92558</td><td>&radic;</td><td>&radic;</td><td>&radic;</td><td>Wiskott-Aldrich syndrome protein family member 1 (WASP-family protein member 1) (Verprolin homology domain-containing protein 1)</td></tr><tr><td>PDE4D_human &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b049">49</xref>&rsqb;</td><td>Q08499</td><td>&radic;</td><td>&radic;</td><td>&radic;</td><td>cAMP-specific 3&prime;,5&prime;-cyclic phosphodiesterase 4D</td></tr><tr><td>Abi1_human &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b050">50</xref>&rsqb;</td><td>Q8IZP0</td><td>&radic;</td><td>&radic;</td><td>&times;</td><td>Abl-interactor 1 (Abelson interactor 1) (Abi-1) (Spectrin SH3 domain-binding protein 1) (Eps8 SH3 domain-binding protein) (Eps8 binding protein) (e3B1) (Nap1 binding protein) (Nap1BP) (Abl binding protein 4) (AblBP4)</td></tr><tr><td>CABL2_mouse &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b039">39</xref>&rsqb;</td><td>NP_665850</td><td>&times;</td><td>&times;</td><td>&times;</td><td>Cdk5 and Abl enzyme substrate 2 (interactor with cdk3 2) (ik3&ndash;2)</td></tr><tr><td>ENAH_mouse &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b051">51</xref>&rsqb;</td><td>Q03173</td><td>&radic;</td><td>&radic;</td><td>&radic;</td><td>Enabled protein homolog (NPC derived proline-rich protein 1) (NDPP-1)</td></tr><tr><td>SEM6D_mouse &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b035">35</xref>&rsqb;</td><td>NP_954711</td><td>&times;</td><td>&times;</td><td>&times;</td><td>Semaphorin 6D</td></tr><tr><td>CRK_human &lsqb;<xref ref-type="bibr" rid="pcbi-0020001-b052">52</xref>&rsqb;</td><td>P46108</td><td>&radic;</td><td>&times;</td><td>&times;</td><td>Proto-oncogene C-crk</td></tr></tbody></table> --></disp-formula><p>where Δ<italic>E<sub>MM</sub></italic> is the molecular mechanics interaction energy between the SH3 domain and the peptide, Δ<italic>G<sub>PB</sub></italic> and Δ<italic>G<sub>SA</sub></italic> are the electrostatic and non-polar contributions to desolvation upon peptide binding, respectively, and −<italic>T</italic>Δ<italic>S</italic> is the conformational entropy change. To consider the conformational flexibility of the peptide, we ran two separate MD simulations on the complex and the free peptide to calculate the binding free energy [<xref ref-type="bibr" rid="pcbi-0020001-b016">16</xref>].</p><p>Δ<italic>E<sub>MM</sub></italic> was calculated using the <italic>sander</italic> program in AMBER 8 [<xref ref-type="bibr" rid="pcbi-0020001-b019">19</xref>]. Δ<italic>G<sub>PB</sub></italic> was calculated using the <italic>pbsa</italic> program in AMBER 8. The grid size used to solve the Poisson-Boltzmann equation was 0.5 Å, and the values of interior dielectric constant and exterior dielectric constant were set to 1 and 80, respectively (the influence of the interior dielectric constant value to the free energy calculation is discussed in Supporting Information). Δ<italic>G<sub>SA</sub></italic> was estimated from the surface area [<xref ref-type="bibr" rid="pcbi-0020001-b016">16</xref>, <xref ref-type="bibr" rid="pcbi-0020001-b044">44</xref>]. The peptide-SH3 interaction energies were calculated from 150 snapshots taken from 300 ps to 1.2 ns MD simulation trajectories of the complex. 160 snapshots taken from 400 ps to 2.0 ns MD simulations on the unbound peptides were used to calculate the conformational energy change for the peptides.</p><p>The normal mode analysis was performed to estimate the vibrational component of the entropy using the <italic>nmode</italic> program in AMBER 8 [<xref ref-type="bibr" rid="pcbi-0020001-b019">19</xref>]. In the absence of solvent, the structures (complex, SH3, and peptide) were minimized with no cutoff for non-bonded interactions, by using conjugate gradient and then Newton-Raphson minimizations until the root mean square of the elements of gradient vector was less than 5 × 10<sup>−5</sup> kcal/mol. Then, normal mode calculations were carried out with no cutoff for non-bonded interactions. A distance-dependent dielectric constant (ɛ = 4<italic>R</italic><sub>ij</sub>) was used to mimic solvent screening. Frequencies of the vibrational modes were computed at 300K for these minimized structures and using a harmonic approximation of the energies. Due to the high computational demand, only 25 snapshots taken from MD were used to estimate −TΔS.</p></sec><sec id="s4c"><title>The VM method.</title><p>To investigate the preference of residues at each position, systematic single point mutation was performed on the peptide. The peptide APSYSPPPPP in the crystal structure 1bbz was used as the template. Each residue of the peptide was mutated to the other 19 residues using the <italic>scap</italic> program [<xref ref-type="bibr" rid="pcbi-0020001-b041">41</xref>]. Minimization, MD simulations, and MM/PBSA calculations were performed on all 190 mutated complexes, as well as on the free peptides using the same set-up described above. Assuming mutating a single residue of the peptide did not significantly change the peptide conformation, we did not include the conformational entropy in the comparison of 20 residues at each position.</p></sec><sec id="s4d"><title>Single point mutation free energy profile and database scan.</title><p>The SPMFEP is a 10 × 20 matrix, which represents the difference between the binding free energies of the mutated peptides and the template peptide APSYSPPPPP (<xref ref-type="table" rid="pcbi-0020001-t002">Table 2</xref>). SPMFEP can be used as a position specific scoring matrix. The score of each peptide is calculated as: <inline-formula id="pcbi-0020001-ex001"><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.0020001.ex001" xlink:type="simple"/></inline-formula>
					, where <italic>M<sub>S,i</sub></italic> is the score of the amino acid <italic>S</italic> at <italic>i<sup>th</sup></italic> position in the SPMFEP and <italic>S<sub>i</sub></italic> is the amino acid at the <italic>i<sup>th</sup></italic> position of the peptide. All ten-residue-long peptides in the SWISS-PROT database (release 46.4) were scored using the SPMFEP. The Perl script used for the database scan is available upon request.
				</p></sec></sec><sec id="s5"><title>Supporting Information</title><supplementary-material id="pcbi-0020001-sg001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.sg001" xlink:type="simple"><label>Figure S1</label><caption><title>The Correlations between the Experimental and Calculated Relative Binding Free Energies Using an Interior Dielectric Constant of 2</title><p>(249 KB TIF)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-sg002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.sg002" xlink:type="simple"><label>Figure S2</label><caption><title>The Superposition of 23 Snapshots Extracted from the MD Trajectory from 0.1 ns to 1.2 ns</title><p>The structure of SH3 shown here was extracted from the snapshot at 0.1 ns. The residues at P<sub>3</sub>, P<sub>−3</sub>, P<sub>−4</sub>, P<sub>−5,</sub> and P<sub>−6</sub> of the peptide are colored in red and other residues are colored according to residue type defined in Insight II.</p><p>(2.9 MB TIF)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-sg003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.sg003" xlink:type="simple"><label>Figure S3</label><caption><title>The Fluctuations of the Free Energy Components</title><p>PB represents the polar contribution to the solvation free energy (ΔGPB). Electrostatic means the electrostatic interaction between the peptide and the SH3 domain (ΔEele), and van de Waals means the van de Waals interactions between the peptide and the SH3 domain (ΔEvdw).</p><p>(358 KB TIF)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-sg004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.sg004" xlink:type="simple"><label>Figure S4</label><caption><title>The Interactions between Peptide FGTYPPPLPP and the Abl SH3 Domain</title><p>Two residues, Trp36 and Trp47, are shown in stick, and the peptide is shown in ball-and-stick.</p><p>(942 KB TIF)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-sd001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.sd001" xlink:type="simple"><label>Protocol S1</label><caption><title>The MM/PBSA Calculations Protocols and the Conformational Changes of Ligands in Peptide Binding</title><p>(42 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st001" xlink:type="simple"><label>Table S1</label><caption><title>The Energetic Components and Binding Affinities for 20 Non-Binders (kcal/mol)</title><p>(66 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st002" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st002" xlink:type="simple"><label>Table S2</label><caption><title>The Energetic Components and Binding Affinities for the 15 Peptide Ligands of the Abl SH3 Domain Using Interior Dielectric Constant of 2 (kcal/mol)</title><p>(56 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st003" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st003" xlink:type="simple"><label>Table S3</label><caption><title>The Binding Free Energies for 20 Peptides Mutated at Position P<sub>−5</sub> (kcal/mol)</title><p>(63 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st004" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st004" xlink:type="simple"><label>Table S4</label><caption><title>The Binding Free Energies for 20 Peptides Mutated at Position P<sub>−3</sub> (kcal/mol)</title><p>(62 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st005" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st005" xlink:type="simple"><label>Table S5</label><caption><title>The Binding Free Energies for 20 Peptides Mutated at Position P<sub>0</sub> (kcal/mol)</title><p>(61 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st006" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st006" xlink:type="simple"><label>Table S6</label><caption><title>The Binding Free Energies for 20 Peptides Mutated at Position P<sub>3</sub> (kcal/mol)</title><p>(65 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st007" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st007" xlink:type="simple"><label>Table S7</label><caption><title>The Contribution of Each Residue in Peptide APSYSPPPPP to the SH3 Binding (kcal/mol)</title><p>(57 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st008" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st008" xlink:type="simple"><label>Table S8</label><caption><title>The High-Rank Peptides Selected by PMFEP, Scansite, and iSPOT in 13 Abl SH3-Binding Proteins</title><p>(54 KB DOC)</p></caption></supplementary-material><supplementary-material id="pcbi-0020001-st009" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.0020001.st009" xlink:type="simple"><label>Table S9</label><caption><title>The Top 600 Sequences Found in Human Proteins from Database Search</title><p>(643 KB DOC)</p></caption></supplementary-material><sec id="s5a"><title>Accession Numbers</title><p>The Swiss-Prot and TrEMBL (<ext-link ext-link-type="uri" xlink:href="http://www.expasy.org/sprot" xlink:type="simple">http://www.expasy.org/sprot</ext-link>) accession numbers for the genes and gene products discussed in this paper are: 1bb9 (1bb9), 1bbz (CAB04591), 1cka (CAA18266), 1gbq (1gbqa), 3BP1_human (Q9Y3L3), 3BP1_mouse (P55194), 3BP2 (P78314), 3BP2_mouse (Q06649), AD08 (P78325), AT19 (Q8TE59), CABL2_human (NP_665850), DYN2 (P50570), EVL (Q9UI08), P73_human (O15350), PRL3 (P02814), RBMG (Q9UPN6), RX (Q9Y2V3), SCA3 (O14828), SEM6A (Q9H2E6), SEM6D (Q76KF3), SEM6D_mouse (NP_954711), SEP4 (O43236), TACT (P40200), WASF1 (Q92558), and WASF4 (Q8IV90).</p></sec></sec></body><back><ack><p>The MD simulations were performed on the Linux cluster in the Center for Theoretical Biological Physics (CTBP) at UCSD. This work has been supported by the National Science Foundation PFC-sponsored Center for Theoretical Biological Physics (grants PHY-0216576 and PHY-0225630). TH is supported by a CTBP postdoctoral scholarship. BL is supported by a National Institutes of Health grant to the McCammon group (GM31749). WAM is supported by a NIH training grant (5-T32DK07233). We thank Prof. J. Andrew McCammon for providing access to computer software such as Insight II.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>MD</term><def><p>molecular dynamics</p></def></def-item><def-item><term>MM/PBSA</term><def><p>Molecular Mechanics/Poisson-Boltzmann Solvent Area</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>SH2</term><def><p>Src Homology 2 domain</p></def></def-item><def-item><term>SH3</term><def><p>Src Homology 3 domain</p></def></def-item><def-item><term>SPMFEP</term><def><p>single position mutation free energy profile</p></def></def-item><def-item><term>VM</term><def><p>virtual mutagenesis</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pcbi-0020001-b001"><label>1</label><element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">Russell RB, Alber F, Aloy P, Davis FP, Korkin D, et al</collab>
					<year>2004</year>
					<article-title>A structural perspective on protein-protein interactions.</article-title>
					<source>Curr Opin Struct Biol</source>
					<volume>14</volume>
					<fpage>313</fpage>
					<lpage>324</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b002"><label>2</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>WA</given-names></name><name name-style="western"><surname>Richards</surname><given-names>FM</given-names></name><name name-style="western"><surname>Fox</surname><given-names>RO</given-names></name></person-group>
					<year>1994</year>
					<article-title>Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains.</article-title>
					<source>Nature</source>
					<volume>372</volume>
					<fpage>375</fpage>
					<lpage>379</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b003"><label>3</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>SB</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JK</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Simon</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>SL</given-names></name></person-group>
					<year>1994</year>
					<article-title>Two binding orientations for peptides to the src SH3 domain: Development of a general model for SH3-ligand interactions.</article-title>
					<source>Science</source>
					<volume>266</volume>
					<fpage>1241</fpage>
					<lpage>1247</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b004"><label>4</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Macias</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hyvonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Baraldi</surname><given-names>E</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>J</given-names></name><name name-style="western"><surname>Sudol</surname><given-names>M</given-names></name><etal/></person-group>
					<year>1996</year>
					<article-title>Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide.</article-title>
					<source>Nature</source>
					<volume>382</volume>
					<fpage>646</fpage>
					<lpage>649</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b005"><label>5</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Kuriyan</surname><given-names>J</given-names></name><name name-style="western"><surname>Cowburn</surname><given-names>D</given-names></name></person-group>
					<year>1997</year>
					<article-title>Modular peptide recognition domains in eukaryotic signaling.</article-title>
					<source>Annu Rev Biophys Biomol Struct</source>
					<volume>26</volume>
					<fpage>259</fpage>
					<lpage>288</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b006"><label>6</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Mahoney</surname><given-names>NM</given-names></name><name name-style="western"><surname>Rozwarski</surname><given-names>DA</given-names></name><name name-style="western"><surname>Fedorov</surname><given-names>E</given-names></name><name name-style="western"><surname>Federov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Almo</surname><given-names>SC</given-names></name></person-group>
					<year>1999</year>
					<article-title>Profilin binds proline-rich ligands in two distinct amide backbone orientations.</article-title>
					<source>Nat Struct Biol</source>
					<volume>6</volume>
					<fpage>666</fpage>
					<lpage>671</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b007"><label>7</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>SY</given-names></name></person-group>
					<year>1999</year>
					<article-title>Recognition and regulation of primary-sequence motifs by signaling modular domains.</article-title>
					<source>Prog Biophys Mol Biol</source>
					<volume>71</volume>
					<fpage>359</fpage>
					<lpage>372</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b008"><label>8</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Dalgarno</surname><given-names>DC</given-names></name><name name-style="western"><surname>Botfield</surname><given-names>MC</given-names></name><name name-style="western"><surname>Rickles</surname><given-names>RJ</given-names></name></person-group>
					<year>1998</year>
					<article-title>SH3 domains and drug design: Ligands, structure, and biological function.</article-title>
					<source>Biopolymers</source>
					<volume>43</volume>
					<fpage>383</fpage>
					<lpage>400</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b009"><label>9</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Cesareni</surname><given-names>G</given-names></name><name name-style="western"><surname>Panni</surname><given-names>S</given-names></name><name name-style="western"><surname>Nardelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Castagnoli</surname><given-names>L</given-names></name></person-group>
					<year>2002</year>
					<article-title>Can we infer peptide recognition specificity mediated by SH3 domains?</article-title>
					<source>FEBS Lett</source>
					<volume>513</volume>
					<fpage>38</fpage>
					<lpage>44</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b010"><label>10</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Zarrinpar</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>RP</given-names></name><name name-style="western"><surname>Lim</surname><given-names>WA</given-names></name></person-group>
					<year>2003</year>
					<article-title>The structure and function of proline recognition domains.</article-title>
					<source>Sci STKE</source>
					<volume>203</volume>
					<fpage>RE8</fpage>
				</element-citation></ref><ref id="pcbi-0020001-b011"><label>11</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Rickles</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Botfield</surname><given-names>MC</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>XM</given-names></name><name name-style="western"><surname>Henry</surname><given-names>PA</given-names></name><name name-style="western"><surname>Brugge</surname><given-names>JS</given-names></name><etal/></person-group>
					<year>1995</year>
					<article-title>Phage display selection of ligand residues important for Src homology 3 domain-binding specificity.</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<volume>92</volume>
					<fpage>10909</fpage>
					<lpage>10913</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b012"><label>12</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Sparks</surname><given-names>AB</given-names></name><name name-style="western"><surname>Rider</surname><given-names>JE</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>NG</given-names></name><name name-style="western"><surname>Fowlkes</surname><given-names>DM</given-names></name><name name-style="western"><surname>Quillam</surname><given-names>LA</given-names></name><etal/></person-group>
					<year>1996</year>
					<article-title>Distinct ligand preferences of Src homology 3 domain from Src, Yes, Abl, Cortactin, p53bp2, Plc-g, Crk, and Grb2.</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<volume>93</volume>
					<fpage>1540</fpage>
					<lpage>1544</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b013"><label>13</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Obenauer</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cantley</surname><given-names>LC</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>MB</given-names></name></person-group>
					<year>2003</year>
					<article-title>Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs.</article-title>
					<source>Nucleic Acids Res</source>
					<volume>31</volume>
					<fpage>3635</fpage>
					<lpage>3641</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b014"><label>14</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Brannetti</surname><given-names>B</given-names></name><name name-style="western"><surname>Via</surname><given-names>A</given-names></name><name name-style="western"><surname>Cestra</surname><given-names>G</given-names></name><name name-style="western"><surname>Cesareni</surname><given-names>G</given-names></name><name name-style="western"><surname>Helmer Citterich</surname><given-names>M</given-names></name></person-group>
					<year>2000</year>
					<article-title>SH3-SPOT: An algorithm to predict preferred ligands to different members of the SH3 gene family.</article-title>
					<source>J Mol Biol</source>
					<volume>298</volume>
					<fpage>313</fpage>
					<lpage>328</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b015"><label>15</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Wollacott</surname><given-names>AM</given-names></name><name name-style="western"><surname>Desjarlais</surname><given-names>JR</given-names></name></person-group>
					<year>2001</year>
					<article-title>Virtual interaction profiles of proteins.</article-title>
					<source>J Mol Biol</source>
					<volume>313</volume>
					<fpage>317</fpage>
					<lpage>342</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b016"><label>16</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Kollman</surname><given-names>PA</given-names></name><name name-style="western"><surname>Massova</surname><given-names>I</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>B</given-names></name><name name-style="western"><surname>Huo</surname><given-names>SH</given-names></name><etal/></person-group>
					<year>2000</year>
					<article-title>Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models.</article-title>
					<source>Acc Chem Res</source>
					<volume>33</volume>
					<fpage>889</fpage>
					<lpage>897</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b017"><label>17</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Pisabarro</surname><given-names>MT</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>L</given-names></name></person-group>
					<year>1996</year>
					<article-title>Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain.</article-title>
					<source>Biochemistry</source>
					<volume>35</volume>
					<fpage>10634</fpage>
					<lpage>10640</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b018"><label>18</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Kollman</surname><given-names>PA</given-names></name></person-group>
					<year>2000</year>
					<article-title>Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model.</article-title>
					<source>J Mol Biol</source>
					<volume>303</volume>
					<fpage>567</fpage>
					<lpage>582</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b019"><label>19</label><element-citation publication-type="other" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Case</surname><given-names>DA</given-names></name><name name-style="western"><surname>Darden</surname><given-names>TA</given-names></name><name name-style="western"><surname>Cheatham</surname><given-names>IIITE</given-names></name><name name-style="western"><surname>Simmerling</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>
					<year>2004</year>
					<source>AMBER: Assisted model building with energy refinement, version 8 [computer program]</source>
					<publisher-loc>San Francisco</publisher-loc>
					<publisher-name>University of California San Francisco</publisher-name>
				</element-citation></ref><ref id="pcbi-0020001-b020"><label>20</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Froloff</surname><given-names>N</given-names></name><name name-style="western"><surname>Windemuth</surname><given-names>A</given-names></name><name name-style="western"><surname>Honig</surname><given-names>B</given-names></name></person-group>
					<year>1997</year>
					<article-title>On the calculation of binding free energies using continuum methods: Application to MHC class I protein-peptide interactions.</article-title>
					<source>Protein Sci</source>
					<volume>6</volume>
					<fpage>1293</fpage>
					<lpage>1301</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b021"><label>21</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Donnini</surname><given-names>S</given-names></name><name name-style="western"><surname>Juffer</surname><given-names>AH</given-names></name></person-group>
					<year>2003</year>
					<article-title>Calculation of affinities of peptides for proteins.</article-title>
					<source>J Comput Chem</source>
					<volume>25</volume>
					<fpage>393</fpage>
					<lpage>411</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b022"><label>22</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Villanueva</surname><given-names>J</given-names></name><name name-style="western"><surname>Fernández-Ballester</surname><given-names>G</given-names></name><name name-style="western"><surname>Querol</surname><given-names>E</given-names></name><name name-style="western"><surname>Aviles</surname><given-names>FX</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>L</given-names></name></person-group>
					<year>2003</year>
					<article-title>Ligand screening by exoproteolysis and mass spectrometry in combination with computer modeling.</article-title>
					<source>J Mol Biol</source>
					<volume>330</volume>
					<fpage>1039</fpage>
					<lpage>1048</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b023"><label>23</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Rickles</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Botfield</surname><given-names>MC</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>JA</given-names></name><name name-style="western"><surname>Green</surname><given-names>OM</given-names></name><etal/></person-group>
					<year>1994</year>
					<article-title>Identification of Src, Fyn, Lyn, PI3K, and Abl SH3 domain ligands by screening a random phage display library.</article-title>
					<source>EMBO J</source>
					<volume>13</volume>
					<fpage>5598</fpage>
					<lpage>5604</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b024"><label>24</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>ZG</given-names></name><name name-style="western"><surname>Rickles</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Feng</surname><given-names>SB</given-names></name><name name-style="western"><surname>Richard</surname><given-names>S</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>AS</given-names></name><etal/></person-group>
					<year>1995</year>
					<article-title>Structure-function analysis of SH3 domains: SH3 binding-specificity altered by single amino acid substitutions.</article-title>
					<source>Mol Cell Biol</source>
					<volume>15</volume>
					<fpage>5627</fpage>
					<lpage>5634</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b025"><label>25</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Pisabarro</surname><given-names>MT</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>L</given-names></name><name name-style="western"><surname>Wilmanns</surname><given-names>M</given-names></name></person-group>
					<year>1998</year>
					<article-title>Crystal structure of the Abl-SH3 domain complexed with a designed high-affinity peptide ligand: Implications for SH3-ligand interactions.</article-title>
					<source>J Mol Biol</source>
					<volume>281</volume>
					<fpage>513</fpage>
					<lpage>521</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b026"><label>26</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>XD</given-names></name><name name-style="western"><surname>Knudsen</surname><given-names>B</given-names></name><name name-style="western"><surname>Feller</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Sali</surname><given-names>A</given-names></name><etal/></person-group>
					<year>1995</year>
					<article-title>Structural basis for the specific interaction of lysine-containing proline-rich peptides with the n-terminal SH3 domain of c-Crk.</article-title>
					<source>Structure</source>
					<volume>3</volume>
					<fpage>215</fpage>
					<lpage>226</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b027"><label>27</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Wittekind</surname><given-names>M</given-names></name><name name-style="western"><surname>Mapelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>V</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>V</given-names></name><name name-style="western"><surname>Friedrichs</surname><given-names>MS</given-names></name><etal/></person-group>
					<year>1997</year>
					<article-title>Solution structure of the Grb2 N-terminal SH3 domain complexed with a ten-residue peptide derived from SOS: Direct refinement against NOEs, J-couplings, and 1H and 13C chemical shifts.</article-title>
					<source>J Mol Biol</source>
					<volume>267</volume>
					<fpage>933</fpage>
					<lpage>952</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b028"><label>28</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Owen</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Wigge</surname><given-names>P</given-names></name><name name-style="western"><surname>Vallis</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moore</surname><given-names>JD</given-names></name><name name-style="western"><surname>Evans</surname><given-names>PR</given-names></name><etal/></person-group>
					<year>1998</year>
					<article-title>Crystal structure of the amphiphysin-2 SH3 domain and its role in the prevention of dynamin ring formation.</article-title>
					<source>EMBO J</source>
					<volume>17</volume>
					<fpage>5273</fpage>
					<lpage>5285</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b029"><label>29</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Honig</surname><given-names>B</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>A</given-names></name></person-group>
					<year>1995</year>
					<article-title>Classical electrostatics in biology and chemistry.</article-title>
					<source>Science</source>
					<volume>268</volume>
					<fpage>1144</fpage>
					<lpage>1149</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b030"><label>30</label><element-citation publication-type="other" xlink:type="simple">
					<collab xlink:type="simple">Accelrys</collab>
					<year>2000</year>
					<source>Insight II 2000 User Guide [computer program]</source>
					<publisher-loc>San Diego (California)</publisher-loc>
					<publisher-name>Accelrys</publisher-name>
				</element-citation></ref><ref id="pcbi-0020001-b031"><label>31</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lim</surname><given-names>WA</given-names></name><name name-style="western"><surname>Jakalian</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JM</given-names></name><etal/></person-group>
					<year>2001</year>
					<article-title>An analysis of the interactions between the Sem-5 SH3 domain and its ligands using molecular dynamics, free energy calculations, and sequence analysis.</article-title>
					<source>J Am Chem Soc</source>
					<volume>123</volume>
					<fpage>3986</fpage>
					<lpage>3994</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b032"><label>32</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Turck</surname><given-names>CW</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>FE</given-names></name><name name-style="western"><surname>Zuckermann</surname><given-names>RN</given-names></name><name name-style="western"><surname>Lim</surname><given-names>WA</given-names></name></person-group>
					<year>1998</year>
					<article-title>Exploiting the basis of proline recognition by SH3 and WW domains: Design of N-substituted inhibitors.</article-title>
					<source>Science</source>
					<volume>292</volume>
					<fpage>2088</fpage>
					<lpage>2092</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b033"><label>33</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Westphal</surname><given-names>RS</given-names></name><name name-style="western"><surname>Soderling</surname><given-names>SH</given-names></name><name name-style="western"><surname>Alto</surname><given-names>NM</given-names></name><name name-style="western"><surname>Langeberg</surname><given-names>LK</given-names></name><name name-style="western"><surname>Scott</surname><given-names>JD</given-names></name></person-group>
					<year>2000</year>
					<article-title>Scar/WAVE-1, a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffold.</article-title>
					<source>EMBO J</source>
					<volume>19</volume>
					<fpage>4589</fpage>
					<lpage>4600</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b034"><label>34</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Lambrechts</surname><given-names>A</given-names></name><name name-style="western"><surname>Kwiatkowski</surname><given-names>AV</given-names></name><name name-style="western"><surname>Lanier</surname><given-names>LM</given-names></name><name name-style="western"><surname>Bear</surname><given-names>JE</given-names></name><name name-style="western"><surname>Vandekerckhove</surname><given-names>J</given-names></name><etal/></person-group>
					<year>2000</year>
					<article-title>cAMP-dependent protein kinase phosphorylation of EVL, a mena/VASP relative, regulates its interaction with actin and SH3 domains.</article-title>
					<source>J Biol Chem</source>
					<volume>275</volume>
					<fpage>36143</fpage>
					<lpage>36151</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b035"><label>35</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Toyofuku</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Kumanogoh</surname><given-names>A</given-names></name><name name-style="western"><surname>Takegahara</surname><given-names>N</given-names></name><name name-style="western"><surname>Yabuki</surname><given-names>M</given-names></name><etal/></person-group>
					<year>2004</year>
					<article-title>Guidance of myocardial patterning in cardiac development by Sema6D reverse signaling.</article-title>
					<source>Nat Cell Biol</source>
					<volume>6</volume>
					<fpage>1204</fpage>
					<lpage>1211</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b036"><label>36</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Bader</surname><given-names>GD</given-names></name><name name-style="western"><surname>Betel</surname><given-names>D</given-names></name><name name-style="western"><surname>Hogue</surname><given-names>CWV</given-names></name></person-group>
					<year>2003</year>
					<article-title>BIND: The Biomolecular Interaction Network Database.</article-title>
					<source>Nucleic Acids Res</source>
					<volume>31</volume>
					<fpage>248</fpage>
					<lpage>250</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b037"><label>37</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Zanzoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Montecchi-Palazzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Quondam</surname><given-names>M</given-names></name><name name-style="western"><surname>Ausiello</surname><given-names>G</given-names></name><name name-style="western"><surname>Helmer-Citterich</surname><given-names>M</given-names></name><etal/></person-group>
					<year>2002</year>
					<article-title>MINT: A Molecular INTeraction database.</article-title>
					<source>FEBS Lett</source>
					<volume>513</volume>
					<fpage>135</fpage>
					<lpage>140</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b038"><label>38</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Agami</surname><given-names>R</given-names></name><name name-style="western"><surname>Blandino</surname><given-names>G</given-names></name><name name-style="western"><surname>Oren</surname><given-names>M</given-names></name><name name-style="western"><surname>Shaul</surname><given-names>Y</given-names></name></person-group>
					<year>1999</year>
					<article-title>Interaction of c-Abl and p73 alpha and their collaboration to induce apoptosis.</article-title>
					<source>Nature</source>
					<volume>399</volume>
					<fpage>809</fpage>
					<lpage>813</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b039"><label>39</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>H</given-names></name><name name-style="western"><surname>Nishimoto</surname><given-names>I</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>M</given-names></name></person-group>
					<year>2002</year>
					<article-title>ik3–2, a relative to ik3–1/Cables, is associated with cdk3, cdk5, and c-abl.</article-title>
					<source>Biochim Biophys Acta</source>
					<volume>19</volume>
					<fpage>157</fpage>
					<lpage>163</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b040"><label>40</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MC</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>G</given-names></name><etal/></person-group>
					<year>2003</year>
					<article-title>A point-charge force field for molecular mechanics simulations of proteins.</article-title>
					<source>J Comput Chem</source>
					<volume>24</volume>
					<fpage>1999</fpage>
					<lpage>2012</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b041"><label>41</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Honig</surname><given-names>B</given-names></name></person-group>
					<year>2001</year>
					<article-title>Extending the accuracy limits of prediction of side-chain conformations.</article-title>
					<source>J Mol Biol</source>
					<volume>311</volume>
					<fpage>421</fpage>
					<lpage>430</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b042"><label>42</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Darden</surname><given-names>T</given-names></name><name name-style="western"><surname>York</surname><given-names>D</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>L</given-names></name></person-group>
					<year>1993</year>
					<article-title>Particale mesh Ewald and N.log(N) method for Ewald sums in large systems.</article-title>
					<source>J Chem Phys</source>
					<volume>98</volume>
					<fpage>10089</fpage>
					<lpage>10092</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b043"><label>43</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Ryckaert</surname><given-names>J</given-names></name><name name-style="western"><surname>Ciccotti</surname><given-names>G</given-names></name><name name-style="western"><surname>Berendsen</surname><given-names>HJC</given-names></name></person-group>
					<year>1977</year>
					<article-title>Numerical-integration of cartesian equations of motion of a system with constraints: Molecular-dynamics of n-alkanes.</article-title>
					<source>J Comput Phys</source>
					<volume>23</volume>
					<fpage>327</fpage>
					<lpage>341</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b044"><label>44</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Donini</surname><given-names>O</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kollman</surname><given-names>PA</given-names></name></person-group>
					<year>2001</year>
					<article-title>Biomolecular simulations: Recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions.</article-title>
					<source>Annu Rev Biophys Biomol Struct</source>
					<volume>30</volume>
					<fpage>211</fpage>
					<lpage>243</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b045"><label>45</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Cicchetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>G</given-names></name><name name-style="western"><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
					<year>1992</year>
					<article-title>Identification of a protein that binds to the SH3 region of abi and is similar to bcr and gap-rho.</article-title>
					<source>Science</source>
					<volume>257</volume>
					<fpage>803</fpage>
					<lpage>806</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b046"><label>46</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>R</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Cicchetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
					<year>1993</year>
					<article-title>Identification of a 10-amino acid proline-rich SH3 binding-site.</article-title>
					<source>Science</source>
					<volume>259</volume>
					<fpage>1157</fpage>
					<lpage>1161</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b047"><label>47</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Glover</surname><given-names>RT</given-names></name><name name-style="western"><surname>Angiolieri</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>S</given-names></name><name name-style="western"><surname>Monaghan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JY</given-names></name><etal/></person-group>
					<year>2000</year>
					<article-title>Interaction of the N-methyl-D-aspartic acid receptor NR2D subunit with the c-Abl tyrosine kinase.</article-title>
					<source>J Biol Chem</source>
					<volume>275</volume>
					<fpage>12725</fpage>
					<lpage>12729</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b048"><label>48</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Wiedmer</surname><given-names>T</given-names></name><etal/></person-group>
					<year>2001</year>
					<article-title>c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1.</article-title>
					<source>J Biol Chem</source>
					<volume>276</volume>
					<fpage>28984</fpage>
					<lpage>18990</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b049"><label>49</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Beard</surname><given-names>MB</given-names></name><name name-style="western"><surname>O'Connell</surname><given-names>JC</given-names></name><name name-style="western"><surname>Bolger</surname><given-names>GB</given-names></name><name name-style="western"><surname>Houslay</surname><given-names>MD</given-names></name></person-group>
					<year>1999</year>
					<article-title>The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains.</article-title>
					<source>FEBS Lett</source>
					<volume>22</volume>
					<fpage>173</fpage>
					<lpage>177</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b050"><label>50</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>A</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Sakaki</surname><given-names>Y</given-names></name></person-group>
					<year>2001</year>
					<article-title>Isolation of hNap1BP which interacts with human Nap1 (NCKAP1) whose expression is down-regulated in Alzheimer's disease.</article-title>
					<source>Gene</source>
					<volume>271</volume>
					<fpage>159</fpage>
					<lpage>169</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b051"><label>51</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Gertler</surname><given-names>FB</given-names></name><name name-style="western"><surname>Niebuhr</surname><given-names>K</given-names></name><name name-style="western"><surname>Reinhard</surname><given-names>M</given-names></name><name name-style="western"><surname>Wehland</surname><given-names>J</given-names></name><name name-style="western"><surname>Soriano</surname><given-names>P</given-names></name></person-group>
					<year>1996</year>
					<article-title>Mena, a relative of VASP and Drosophila enabled, is implicated in the control of microfilament dynamics.</article-title>
					<source>Cell</source>
					<volume>87</volume>
					<fpage>227</fpage>
					<lpage>239</lpage>
				</element-citation></ref><ref id="pcbi-0020001-b052"><label>52</label><element-citation publication-type="journal" xlink:type="simple">
					<person-group person-group-type="author"><name name-style="western"><surname>Donaldson</surname><given-names>LW</given-names></name><name name-style="western"><surname>Gish</surname><given-names>G</given-names></name><name name-style="western"><surname>Pawson</surname><given-names>T</given-names></name><name name-style="western"><surname>Kay</surname><given-names>LE</given-names></name><name name-style="western"><surname>Forman-Kay</surname><given-names>JD</given-names></name></person-group>
					<year>2002</year>
					<article-title>Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide.</article-title>
					<source>Proc Natl Acad Sci USA</source>
					<volume>99</volume>
					<fpage>14053</fpage>
					<lpage>14058</lpage>
				</element-citation></ref></ref-list></back></article>